# Table of Contents

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Welcome Letters</td>
<td>3</td>
</tr>
<tr>
<td>ISTM President</td>
<td>3</td>
</tr>
<tr>
<td>CISTM14 Scientific Program Committee Chairs</td>
<td>5</td>
</tr>
<tr>
<td>CISTM14 Local Organising Committee Chair</td>
<td>7</td>
</tr>
<tr>
<td>Organisation</td>
<td>9</td>
</tr>
<tr>
<td>CISTM14 Scientific Program Committee</td>
<td>9</td>
</tr>
<tr>
<td>CISTM14 Local Organising Committee</td>
<td>10</td>
</tr>
<tr>
<td>CISTM14 Poster and Oral Award Selection Committee</td>
<td>10</td>
</tr>
<tr>
<td>Highlights of the CISTM14 Committee</td>
<td>10</td>
</tr>
<tr>
<td>ISTM Executive Board</td>
<td>10</td>
</tr>
<tr>
<td>ISTM Secretariat Staff</td>
<td>10</td>
</tr>
<tr>
<td>ISTM Information</td>
<td>11</td>
</tr>
<tr>
<td>Sponsors and Exhibitors</td>
<td>13</td>
</tr>
<tr>
<td>Descriptions of Scientific Program Sessions</td>
<td>15</td>
</tr>
<tr>
<td>Important Information</td>
<td>17</td>
</tr>
<tr>
<td>Admittance Badges</td>
<td>17</td>
</tr>
<tr>
<td>Badge Ribbons</td>
<td>17</td>
</tr>
<tr>
<td>Photographs</td>
<td>17</td>
</tr>
<tr>
<td>Wi-Fi Access at the Conference Center</td>
<td>17</td>
</tr>
<tr>
<td>CISTM14 App</td>
<td>17</td>
</tr>
<tr>
<td>CISTM14 Social Media</td>
<td>18</td>
</tr>
<tr>
<td>Speaker Abstracts</td>
<td>18</td>
</tr>
<tr>
<td>Liability</td>
<td>18</td>
</tr>
<tr>
<td>Evaluation Form</td>
<td>18</td>
</tr>
<tr>
<td>CISTM14 Accreditation</td>
<td>18</td>
</tr>
<tr>
<td>Faculty Disclosures</td>
<td>19</td>
</tr>
<tr>
<td>ISTM Charity Donations</td>
<td>21</td>
</tr>
<tr>
<td>Program</td>
<td>21</td>
</tr>
<tr>
<td>Speaker Ready Room</td>
<td>22</td>
</tr>
<tr>
<td>Welcome Reception</td>
<td>22</td>
</tr>
<tr>
<td>Pre CISTM Courses</td>
<td>22</td>
</tr>
<tr>
<td>CISTM14 Onsite Registration Information</td>
<td>22</td>
</tr>
<tr>
<td>Maps of the Québec City Convention Center</td>
<td>23</td>
</tr>
<tr>
<td>Level 2</td>
<td>23</td>
</tr>
<tr>
<td>Level 3</td>
<td>24</td>
</tr>
<tr>
<td>Level 4</td>
<td>25</td>
</tr>
<tr>
<td>CISTM14 Opening Ceremony</td>
<td>27</td>
</tr>
<tr>
<td>CISTM14 Program Schedule</td>
<td>29</td>
</tr>
<tr>
<td>Sunday, 24 May 2015</td>
<td>29</td>
</tr>
<tr>
<td>Monday, 25 May 2015</td>
<td>30</td>
</tr>
<tr>
<td>Tuesday, 26 May 2015</td>
<td>42</td>
</tr>
<tr>
<td>Wednesday, 27 May 2015</td>
<td>54</td>
</tr>
<tr>
<td>Thursday, 28 May 2015</td>
<td>62</td>
</tr>
<tr>
<td>Posters</td>
<td>64</td>
</tr>
<tr>
<td>Sponsored Satellite Programs</td>
<td>93</td>
</tr>
<tr>
<td>ISTM Committee and Group Meetings</td>
<td>95</td>
</tr>
<tr>
<td>Related Society Meetings</td>
<td>97</td>
</tr>
<tr>
<td>Exhibition</td>
<td>99</td>
</tr>
<tr>
<td>Exhibition Schedule</td>
<td>99</td>
</tr>
<tr>
<td>Exhibitor List</td>
<td>100</td>
</tr>
<tr>
<td>Exhibition Floor Plan</td>
<td>101</td>
</tr>
<tr>
<td>Exhibitor Information</td>
<td>102</td>
</tr>
</tbody>
</table>
Welcome to Québec City!
It’s been three years since Québec City was selected as the site of this year’s Conference of the International Society of Travel Medicine. That’s a long time to wait for something that you think is going to be really special and enjoyable. Finally, we are all here together, and I want to welcome you personally, and ensure you that we have tried to do everything we can to make this the best conference possible.

Travel medicine is unique in the way that it combines preventive care, difficult diagnoses, risk management, vaccinology, and practical travel tips, all with the hope of making travel easier and safer around the world, and to draw attention to the diseases that still plague resource-poor countries. The range of topics in our scientific program represents this diversity, and every talk is so well chosen that the main challenge will be deciding which session to attend when there are simultaneous sessions. Knowing that you can’t attend every program, we will be featuring a “Highlights of the Conference” session at 8:00 a.m. Thursday morning, reviewing the most significant talks of the week.
The conference will provide free Wi-Fi to all participants, along with a conference app that will run on your smart phones, tablets, or computers, and provide all the conference information at your fingertips, including the program, abstracts, and meetings. When day is done, you can search the app for specially selected restaurant recommendations from our local organizing committee. Take a moment to note the meetings of the special interest groups and professional groups that exist within ISTM—you are welcome to attend these meetings and join these groups. Hopefully, this will enhance your travel medicine connections and skills.

You will want to plan to spend time in the exposition hall, where we will feature the largest number of exhibitors in recent years. Four satellite programs will also be featured during the week.

The ISTM is proud to announce that we have taken a number of steps to make this conference eco-friendly, including not printing the abstracts, minimizing the number of printed handouts, using recycled paper and even using recycled banners in the making of the conference bags. There will be an active recycling program during the conference.

There are so many people that have contributed in a substantial way to this year’s meeting. Foremost is Diane Nickolson, our executive director, who directly organized this year’s conference for the first time from our office in Atlanta. The Scientific Program Committee did a tremendous amount of work with both skill and good cheer, under the direction of Leo Visser and Christina Greenaway. Leo was also just elected the president-elect of ISTM. The Local Organizing Committee, under the tireless leadership of Yen Bui, sorted through a vast number of options to make your experience in Québec more enjoyable and informative. All of these activities take place under the careful watchfulness of our Secretary-Treasurer, Peter Leggat.

Please take advantage of all that the conference has to offer, but don’t neglect going out with friends in Québec City, a beautiful old town with a distinctly European character. Friendship is one of the key reasons for traveling around the world to attend this meeting, so make sure you take time to enjoy a meal with old and new friends.

I hope to meet as many of you as I can this week. If I don’t, please know that I hope you have a gratifying time at this conference, and will plan to attend our next conference in Barcelona in 2017.

David R Shlim MD
President, ISTM
Dear Colleagues,

On behalf of the Scientific Program Committee we would like to welcome you to the charming and beautiful City of Québec. It is one of the oldest European settlements in North America with a spirit and joie de vivre that reflects its French roots and character. The picturesque setting of Old Québec with its quaint cobblestone streets and stone buildings, its rich history and the blend of cultures is an ideal venue for the 14th Conference of the International Society of Travel Medicine (CISTM14).

Over the past 25 years ISTM has developed into the professional organization representing and serving health care providers working in the field of travel medicine from all over the world. Travel medicine has become a distinct discipline recognized for its specialized knowledge of the global distribution of diseases, health risks associated with travel and preventive and therapeutic measures to mitigate these risks.

In our rapidly globalizing world the geographic distribution of diseases is continuously changing and new diseases are emerging. We need to adapt to these new challenges and more than ever we need to think and act globally. The diversity of travellers with special needs and medical co-morbidities continues to increase,
necessitating Travel Medicine Practitioners to find ways to keep them safe and healthy during travel. New vaccines are being developed providing new tools for prevention whereas many therapies are being lost due to the rapid rise of resistance to antimalarials and antimicrobials agents. In this changing landscape we need to integrate new knowledge and develop methods to make our travel recommendations more evidence-based. Many of these challenging issues will be addressed during this conference.

The scientific program of CISTM14 was developed by carefully considering feedback from ISTM members from the past CISTM meeting and blending proposals for plenaries, symposia and workshops from ISTM members and members of the Scientific Program Committee (SPC) into a diverse, exciting and stimulating program for all of our members. We invited leading experts to present the latest developments in the field of travel medicine but worked hard to balance this with general topics seen in daily practice. We specifically looked for young and upcoming speakers from all around the world. The SPC received 210 abstract submissions from 41 countries which were carefully assessed by the SPC for originality, design and relevance. Of these abstracts, 34 were selected to be presented as oral communications and the remainder will be presented as posters. To provide more in-depth discussion of many of the high quality abstracts received, we will again have poster tours in 6 different topics areas. Finally, we would like to express our appreciation to the ISTM members who contributed by sending suggestions for the different sessions, and to our colleagues on the SPC for their excellent ideas and proposals and for their evaluation of the submitted abstracts. A special thanks goes to the ISTM Secretariat office for their highly professional support.

We look forward to an exciting and stimulating conference where travel medicine professionals from all over the world can exchange ideas, discuss controversial topics and learn about new developments. The conference will also provide the opportunity to reconnect with longtime friends and colleagues, to network and make new contacts, but most of all to have fun. We look forward to an exciting and thought-provoking conference as we strive to improve the practice of Travel Medicine and expand and solidify its scientific base. Welcome to Québec!

Cheers,

Leo G. Visser, The Netherlands  
*CISTM14 Chair*

Christina Greenaway, Canada  
*CISTM14 Co-Chair*

*Associate Chairs:*
Lin Chen, United States of America
Blaise Genton, Switzerland
Karin Leder, Australia
Bonjour,

It is with great pride that I welcome you to Québec City for the 14th Conference of the International Society of Travel Medicine.

I have been a member of ISTM for more than a decade and have found my professional family within the Travel Health community.

Our field is undergoing tremendous growth, with increases in international and intraregional travels, in high-risk travellers and high-risk travels, coupled with professional challenges regarding changes in scopes of practice in many jurisdictions.

The Local Organizing Committee members represent both the diversity of Canada and the diversity of practice in Travel Health. We combine experience, enthusiasm, energy and above all a devotion to the advancement of our discipline.

Our unifying values are best practices based on best available evidence and in the patients’ best interests.

Whether you are new to Travel Health or an experienced practitioner, I am sure you will find the Scientific Program well suited to your needs.

Don’t forget to enjoy all the beautiful things that this charming city has to offer.

I leave you with some French words you might need in Québec,

Merci, je vous aime.

Yen-Giang Bui
Chair, LOC
CISTM14
Organisation

The ISTM greatly appreciates the contributions of time and expertise provided by the following people to the 14th Conference of the International Society of Travel Medicine.

CISTM14 Scientific Committee

Chair: Leo G. Visser, The Netherlands
Co-Chair: Christina Greenaway, Canada
Associate Chairs: Lin Chen, United States of America
Blaise Genton, Switzerland
Karin Leder, Australia

Members:
Ron Behrens, United Kingdom
Andrea Boggild, Canada
Miguel Cabada, Peru
Jane Chiodini, United Kingdom
John Christenson, United States of America
Christina Coyle, United States of America
Jakob Cramer, Germany
Vanessa Field, United Kingdom
Philippe Gautret, France
Fiona Genasi, United Kingdom
Martin Haditsch, Austria
Stefan Hagmann, United States of America
Davidson Hamer, United States of America
Ted Lankester, United Kingdom
Michael Libman, Canada
Poh Lian Lim, Singapore
Alberto Matteeli, Italy
Susan MacDonald, Canada
Marc Mendelson, South Africa
Maria Mileno, United States of America
Silvia Odolini, Italy
Eli Schwartz, Israel
Mike Starr, Australia
Christopher VanTilburg, United States of America
Jenny Visser, New Zealand
Julia Walker, Canada
Pat Walker, United States of America
Claire Wong, New Zealand
Carolyn Zeind, United States of America
Nicholas Zwar, Australia
CISTM14 Local Organising Committee

Chair:
Yen Bui, Montreal, Canada
Anjli Acharya, Calgary, Canada
Darin Cherniwchan, British Columbia, Canada
Suzanne Gagnon, Québec City, Canada
Jay Keystone, Toronto, Canada
Isobel MacPherson, Halifax, Canada
Anne McCarthy, Ottawa, Canada
Brian Stowe, Ottawa, Canada

Members:

CISTM14 Poster and Oral Award Selection Committee:

Gerald Flaherty, Chair, Ireland
Lee Baker, South Africa
Garth Brink, South Africa
Effrossyni Gkrania-Klotsas, United Kingdom
Nancy Piper Jenks, United States of America
Mike Jones, United Kingdom

Highlights of the CISTM14 Committee:

Gerald Flaherty, Chair, Ireland
Elina Erra, Finland
Fiona Genasi, United Kingdom
Ruwandi Kariyawasam, Canada
Michael Klowak, Canada
Brian Stowe, Canada
Jessica Vlot, Netherlands

ISTM Executive Board

President:
David R. Shlim, United States of America
President-Elect:
Annelies Wilder-Smith, Singapore
Immediate Past President:
Fiona Genasi, United Kingdom
Counselors:
Francesco Castelli, Italy
Davidson Hamer, United States of America
Karin Leder: Australia
Marc Mendelson, South Africa

Secretary/Treasurer:
Peter Leggat, Australia
Executive Director:
Diane L. Nickolson, United States of America

ISTM Secretariat Staff

Diane L. Nickolson, Executive Director
Jodi Metzgar, Managing Director of Projects
Elena Axelrod, Data and Finance Manager
Daveen Capers, Member Services Coordinator
Amanda Martin, Marketing Administrative Assistant
Amara Ugwu, Intern
ISTM Mission Statement
The International Society of Travel Medicine (ISTM) is committed to the promotion of healthy and safe travel. In cooperation with health care providers, academic centers, the travel industry and the media, ISTM advocates and facilitates education, service, and research activities in the field of travel medicine. This includes: preventive and curative medicine within many specialties such as tropical medicine, infectious diseases, high altitude physiology, travel related obstetrics, psychiatry, occupational health, military and migration medicine, and environmental health.

ISTM’s specific goals are to:
- promote travel health
- develop guidelines for travel medicine practice
- educate health care professionals, public health professionals, and the travel industry
- provide a scientific focus for travel medicine
- stimulate the professional advancement of travel medicine practice
- promote distribution of rapid information exchange related to travel medicine issues
- facilitate international contacts between practitioners of travel medicine
- promote development and evaluation of safe, effective, preventive and curative interventions
- foster research in travel medicine, including the promotion of international collaborative studies

ISTM Vision Statement
The ISTM is a vibrant and inclusive international society committed to ongoing and sustained contributions to the advancement of the practice and science of travel medicine globally.

---

International Society of Travel Medicine Secretariat
Email: ISTM@ISTM.org | Web: www.ISTM.org | Skypename: ISTM.office
Office hours: Monday - Friday, 9.00 - 17.00 EDT (UTC-04)
Mail and Courier: 1200 Ashwood Parkway, Suite 310, Dunwoody, GA 30338

International Society of Travel Medicine
Established 1991
Promoting healthy travel worldwide
Satellite Symposium
“Exploring new vaccine candidates for travellers’ diseases: norovirus and dengue fever”

Date and time: Monday 25 May 2015, 13:00–14:30

Venue: Room 200Ab, Centre Des Congrès De Québec, Québec City, Canada

Chair: Prof. Dr. Robert Steffen (University of Zurich, Switzerland)

Faculty: Dr. Tomas Jelinek (Berlin Center for Travel and Tropical Medicine, Germany), Prof. Christine Moe (Emory University, USA), Dr. Jakob Cramer (Takeda Vaccine Business Unit, Switzerland)

Presentation topics:
- Travellers’ risk of contracting dengue and norovirus
- Characteristics of dengue: the disease and epidemiology
- Norovirus-related disease and disruption in travel settings
- Advances in vaccine candidates for norovirus and dengue fever

Light refreshments will be provided

This educational symposium has been organised and funded by Takeda

Takeda Vaccine Business Unit
Companies Supporting the CISTM14

The ISTM acknowledges the following CISTM14 confirmed sponsors and exhibitors. We encourage all delegates to visit each of them in the exposition.
Air Ambulance Card
Asia Pacific Travel Health Conference (APTHC)
Astral-Tropimed
Care Plus
CDC Travelers’ Health Branch
Clasado Bimuno
GSK
Global MediKit
Global TravEpiNet
Health Partners International of Canada (HPIC)
iJet International
Immuron
Incaplex Ltd. / IncaClinic
International Association for Medical Assistance to Travellers (IAMAT)
Northern European Conference on Travel Medicine (NECTM)
Oxford University Press (OUP)
Paladin Labs
PanTheryx
PaxVax, Inc.
Royal College of Physicians and Surgeons of Glasgow
Sanofi Pasteur Limited
Shoreland Travax
Sitata
Skin Shield Products
South African Society of Travel Medicine (SASTM)
Steripen by Hydro-Photon, Inc.
Takeda
Tropimed
Valneva
Descriptions of Scientific Program Sessions

Plenary Lectures
The daily plenaries during the meeting are meant to highlight areas at the forefront of travel medicine. In general these are internationally prominent invited speakers with expertise allied to travel medicine who delegates would like to hear, but who would not otherwise attend a travel medicine meeting. Each speaker is typically allotted 30 minutes; there is no discussion period during plenary sessions. There are no concurrent sessions running during plenaries.

Symposium Lectures
Each symposia during the meeting are meant to highlight areas at the forefront of daily travel medicine practice. The topics are more focused than the plenaries and in many cases will appeal most to subsets of delegates with special interests. Each speaker is typically allotted 25 minutes for their presentation with 5 minutes for questions. Symposia are held concurrently with other sessions.

Workshop Sessions
Each workshop session is designed to promote dialogue between 2 experts on a topic in the field of travel medicine and individuals in practice who have experiences to share and questions to ask. While designed to be intimate and interactive, experience indicates that workshop audiences will vary. Practical information that will give participants insight into the most current strategies for prevention, self-treatment, and diagnosis is emphasized. Workshop chairs will have developed a set of clinical scenarios or case histories designed to stimulate discussion/learning. Some workshops are designated as ABC, indicating introductory topics, and some as destination which focus on a particular travel destination. All workshop sessions are concurrent with other sessions.

Debate
The debate during the meeting is meant to highlight a controversial area at the forefront of travel medicine. This format will feature four highly experienced ISTM members who will debate specific issues under the broad topic. There will be opening and closing statements by each of the debaters, and time will be made available for questions from the audience to the debaters. This session will be held concurrently with other sessions.

Free Communications Oral Sessions
Each session free communication will consist of presentations of the latest original research, case studies, or experiences of travel medicine peers. Each presentation will be 10-minutes in length with 5 minutes for questions and discussion. These sessions are concurrent with other sessions.
Posters
Posters are presented on the latest original research, case studies or experiences of travel medicine peers. Posters must be displayed on Monday, 25 May by 10.00, and will be available for viewing from Monday, 25 May 2015 at 10:30 until Wednesday, 27 May 2015 in the Exhibit Hall. Authors will be in attendance on Wednesday, 27 May 2015 from 16:15 to 17:15.

Poster Tours
On Tuesday, 26 May 2015 during the morning and afternoon breaks, special poster tours have been arranged on specific topics. The poster tours are listed in the scientific program schedule, and all delegates are invited to participate.

Meet the History
In the early morning the always popular Meet the History sessions are a lecture series describing historical and cultural background information on the local area that is of particular interest to travel medicine professionals.

Case of the Day
In an early morning session, an expert in travel medicine will present a case from their practice that is both interesting and informative to attending delegates. The cases will raise issues of diagnosis and therapy that will stimulate discussion and participation by those attending.

Abstract Writing
This is a professional development session to help in the writing of abstracts. This session will take place on Wednesday, 27 May, 2015 from 08.00 – 08.45.

Highlights of the Conference
In this early morning session the best information gleaned during the CISTM14 in Québec City will be presented. This session is scheduled on the final day of the CISTM at 08.00-08.45.
Important Information

Admittance Badges
Participants are required to wear their name badges while in attendance. Badges will be checked at the entrance of the exposition and the scientific program meeting rooms. If you have misplaced your badge, registration staff will assist you in securing a replacement.

- Full Delegate Badge: All activities throughout the Conference
- One Day Badge: All activities on the specified day
- Accompanying Person Badge: Welcome Get Together and Exhibit Hall
- Exhibitor Badge: Welcome Get Together and Exhibit Hall
- Persons not wearing an appropriate badge will be denied admission.

Badge Ribbons
If you are entitled to special ribbons for your badge, please go to the registration station where the delegate satchels are being handed out. All new CISTM attendees are encouraged to wear a “First Time Attendee” ribbon.

Photographs
Taking pictures of presenters and slides of the presentations is strictly prohibited. Only the ISTM contracted photographer may take photographs in the scientific program meeting rooms. Please respect the speakers work and do not photograph their slides without permission.

Wi-Fi Access at the Conference Center
ISTM is delighted to be providing free Wi-Fi access for all delegates and participants for the duration of the CISTM14. Each device connected will receive a bandwidth of 3GB with the speed up to 5Mbps.
To access the CISTM14 Wi-Fi simply:
Choose “ISTM” from the available networks.
On the website that appears, select “Access Wireless Internet with Access Code”
When prompted, type the access code CISTM14
Then accept the terms and conditions, select “Connect Now” and you should be connected!

For any technical connection challenges, please contact the provider at +1.418.649.5219.

CISTM14 App
Are you wishing there was one place to find everything you need for CISTM14? Well, NOW THERE IS! Navigate to http://Cumulus.encore-us.com and type in Event ID: 0703-0569. You will be able to access things like the Program Schedule, Abstracts, and Speaker Biographies. We have also linked to our website so you have the most up to date wealth of information, all at your fingertips.
CISTM14 Social Media

Are you going to be sharing your week with friends and family on social media? Have you taken pictures at our Selfie Station at the Entrance? We want to hear and see all about it; make sure you use #CISTM14! Tweet us, Facebook us, and get LinkedIn with us.

Speaker Abstracts

Abstracts from invited speakers, free communication and poster presenters can be found on the special CISTM14 app at http://Cumulus.encore-us.com; type in Event ID: 0703-0569. You can also find the abstracts on the ISTM website (www.istm.org). Once on the website click on the CISTM14 picture on the home page to access the full CISTM14 website. The link to the abstracts can be found in the navigation column on the left side of this page.

Liability

The 14th Conference of the International Society of Travel Medicine in no event shall be liable for acts or defaults in the event of injury, damage, loss, accident, delay or irregularity of any kind whatsoever during arrangements organized through contractors or the employees of such contractors in performing services. The organizers reserve the right to make changes, where deemed necessary, without prior notice to parties concerned.

Evaluation Form

You will find an evaluation form in your conference bag. Please take a few minutes to evaluate the sessions you attend. The form can be returned to the Registration Desk.

CISTM14 Accreditation

Certificates will be available at the CISTM registration desk from Monday afternoon through Thursday morning.

Accreditation for CME has been sought through the Continuing Professional Development (CPD) department, Faculty of Medicine, McGill University.

Accreditation has been acquired by the Ordre des Pharmaciens du Québec, which will grant 19,5 CEU to pharmacists who have folllowed the entire program.

This conference offers a substantial number of Core and Elective Credits for Fellowship in the Academy Of Wilderness Medicine. To determine the exact number of credits you will earn by attending, use the Simulation Tool on the FAWM Eligible Activities Page at WMS.ORG.
## Faculty Disclosures

<table>
<thead>
<tr>
<th>Name</th>
<th>Disclosures</th>
</tr>
</thead>
</table>
| Anjli Acharya               | Sheila Hall  
| Paul M. Arguin             | Davidson Hamer\(^4\)  
| Lee Baker\(^1\)             | Bjorn Heyerdah\(^1\)  
| Elizabeth D. Barnett\(^6\) | Anita Heywood\(^2\)  
| Andrea Boggild              | Jill Hodges  
| Miguel Cabada               | Nancy Piper Jenks  
| Anna-Maria Carvalho\(^8\)  | Eric Johnson  
| Francesco Castelli          | Michael Jones  
| Eric Caumes                 | Jay Keystone  
| Martin Cetron               | Kamran Khan  
| Joannes Clerinx             | Sarah Kohl  
| Simon Clift                 | Camille Kotton  
| Andrea Conroy\(^4\)         | Susan Kuhn  
| Christina M. Coyle          | Regina LaRocque  
| Jakob Cramer                | Colleen Lau  
| Eilif Dahl                  | Peter Leggat\(^1\)  
| Nicholas Day                | Michael Libman  
| Gaston De Serres\(^1\)      | Lisette van Lethout  
| Arthur L. Diskin            | Rogelio Lopez-Velez  
| Carolyn Driver\(^13\)       | Louis Loutan  
| Philippe Duclos             | Beth Lown  
| Philip Fischer              | Sheila Mackell  
| David Freedman\(^10\)       | Alan Magill  
| Cornelia Staehelin Fux      | Anne McCarthy  
| Antoine Geissbuhler         | Ziad A. Memish  
| Fiona Genasi                | Marc Mendelson  
| Perry van Genderen          | Deborah Mills\(^1\)  
| Jeffery Goad\(^12\)         | Oliver Morton  
| Fons Van Gompel\(^19\)      | Paul Newton  
| Larry Goodyer\(^7\)         | Lorraine Noble  
| Natalie Gray                | Jan Von Overbeck  
| Martin Grobusch             | Prativa Pandey  
| Gordon Guyatt               | Philippe Parola  
| Dipti Patel                 | Rui Manuel Correia  
|                            | Pombal\(^9\)  
|                            | Robert Charles Read\(^6\)  
|                            | Reetta Satokari  
|                            | Pat Schlegel  
|                            | Steven Schofield  
|                            | Eli Schwartz  
|                            | Kevin Schwartzman  
|                            | Mary-Louise Scully\(^18\)  
|                            | Makeda Semret  
|                            | Tyler Michael Sharp  
|                            | David Shlim  
|                            | Balbir Singh  
|                            | Erin Staples  
|                            | Mike Starr  
|                            | William Stauffer\(^3\)  
|                            | Elizabeth Talbot  
|                            | Paul Tambayah  
|                            | Grant Tarling  
|                            | Christopher Van Tilburg  
|                            | Joseph Torresi  
|                            | Jenny Visser  
|                            | Erika R. Vliegh  
|                            | Brian Ward  
|                            | Mary Jean Warrell  
|                            | Annellies Wilder-Smith  
|                            | Mary Elizabeth Wilson  
|                            | Claire Wong  
|                            | Cedric Yansouni  
|                            | Caroline Zeind  
|                            | Jakob Zinsstag  
|                            | Nicholas Zwar\(^16\)  

The footnoted Speakers have indicated that they have relationships with the entries listed below which, in the context of their presentation(s), could be perceived as a potential conflict of interest (e.g., direct research funding from a commercial organization, etc.).

1. GlaxoSmithKline – Travel expenses reimbursement to attend an ad hoc advisory board meeting. No honorarium; GlaxoSmithKline – Research grant for Hepatitis B vaccine study and measles vaccine.
2. GlaxoSmithKline Biologicals (current) — Consultation fees for expert advice on travel medicine projects; Sanofi Pasteur (completed) — Investigator-driven grant funding.
3. Critical Measures, LLC – I receive a royalty for intellectual input on an educational product on working across cultures. I will not mention either Critical Measures or the educational product during my talk.
4. Fio Corporation – Inventor on patent owned by Fio on biomarkers of life threatening infections
5. Novartis – Research Grant 2010-2012
Important Information, continued

6.  Lupin—Advisory Board; Elsevier—Royalties; BMJ Point of Care—Grant/Honorarium; Intercell, PaxVax and Cerexa—Clinical Trials Novartis, GlaxoSmithKline, Sigma Tau—honorarium

7.  Norgine, GSK and Sigma Tau—2010-2013 Advisory boards; Nomad Travel Store and Clinics—1900- present Medical Director

8.  Air Canada—Present: Consultant

9.  UCS-TAP Air Portugal Group—Medical Director (since 1998); Lufthansa AG—Designated physician for Lisbon (since 2001)

10.  Shoreland, Inc, UpToDate, Inc, Antimicrobial Therapy, Inc—Writing, Editing, production of information materials related to travel medicine. Ongoing work as of time of CISTM meeting.

11.  Roche, Pfizer, Sanofi Pasteur, Merck Sharpe & Dohme, Biovac., Aspen/ GlaxoSmithKline – 1999 to current, they are clients of my Med Info service; Sanofi Pasteur, Aspen/ GlaxoSmithKline, Merck Sharpe & Dohme, Pfizer – I have given talks on vaccines since 2009

12.  Merck Vaccine – Speakers’ bureau

13.  GlaxoSmithKline, Sanofi, Pasteur, Merck Sharpe & Dohme – Over the last 10 years I have received speaking fees for speaking at educational events sponsored by these companies

14.  Ijet—Member, Health advisory Board 2002-present; Alere, Inc.—I hold equity in this company which produces medical diagnostic products; Yes – all investigator-initiated non funded by the pharmaceutical industry

15.  GlaxoSmithKline, Sanofi, CSL – Various over the years

16.  GlaxoSmithKline (Australia) – Honoria from GlaxoSmithKline Australia for presentation at travel medicine educational events in 2013 and 2014; Sanofi Pasteur Australia – Honoraria from Sanofi Pasteur Australia for presentation at travel medicine education events in 2014


18.  Setpoint Medical—Husband employed by Setpoint, and holds some equity in the company

19.  GlaxoSmithKline, Abbvie – financial support for attending conferences (yearly), speaking at local symposia (sporadically) and writing brochures on travel medicine (biennially)

ADDENDUM

The following faculty or planners have declared potential membership in a Speaker’s Bureau.

Planner:
Leo Visser
Declared Abbott, Crucell, Sanofi Speaker’s Bureau
Dr. Visser is a Speaker Honoree, not a member of a Speaker’s Bureau. He is the CISTM14 Scientific Program Chair and will not be leading any sessions

Symposium 10
Karl M. Hess
Merck Speaker’s Bureau
Dr. Hess has declared that no Merck material or slides will be used in his session.

Workshop 10
Jeffery Goad
Merck and Intercell Speaker’s Bureau
Dr. Goad has declared that no Merck or Intercell material or slides will be used in his session.

Workshop 11
Patricia Schlagenhausn
Sigma Tau Speaker’s Bureau
Dr. Schlagenhausn has declared that no Sigma Tau material or slides will be used in her session.
ISTM Charity Donations Program

Thank you to those who have already donated to this program. It is not too late to participate in this opportunity to enhance your ability to assist the less fortunate throughout the world. The ISTM pledge is to equally match each dollar donated by CISTM14 delegates to the charities listed below up to a maximum of USD 15,000. This is your opportunity to maximize your contributions to these worthy organizations focused on serving people in resource poor countries. Each of these organizations was recommended by members of the ISTM, and you can learn more about them by consulting their websites.

The eligible organizations are:

Cardiostart International (www.cardiostart.org) - Providing free heart surgery and medical services to children and adults living in resource poor countries. Recent areas served include Uganda, Peru, Ghana and Brazil.

Early Childhood Development Center (http://ecdcnepal.org/newportal) - Dedicated to helping the children of imprisoned parents in Nepal.

HOPE Foundation for Women and Children of Bangladesh (http://www.hopeforbangladesh.org) - Aim is to provide health services to needy people in Bangladesh, particularly the women and children in rural areas.

Langtang Valley Health (http://langtangvalleyhealth.org) - Providing primary health and emergency medical care to the inhabitants of and visitors to the Langtang region of Nepal.

Nomads Clinic (http://nomadsclinic.org) - Training local healthcare providers and meeting the needs of those who live in the Humla and Mustang Regions of Nepal.

Symbiosis International (http://symbiosis-int.org) - Working toward empowerment and development of community-based organizations in Bangladesh.

ISTM makes no representations as to deductibility or other legal or tax consequences of any registrant’s contributions to these organizations, since such matters are determined by the laws of both the recipient’s location and the donor’s place of tax residency, as well as the donor’s personal tax and financial circumstances. Each potential donor is advised to consult with his or her financial and tax advisers to determine the consequences to him or her of such a donation.
Important Information, continued

**Speaker Ready Room**
The Speaker Ready room is located in room 201A on Level 2. The Speaker Ready Room hours are as follows:

- **Sunday, 24 May 2015**: 14.00 - 18.00
- **Monday, 25 May 2015**: 07.30 - 18.30
- **Tuesday, 26 May 2015**: 07.30 - 18.30
- **Wednesday, 27 May 2015**: 07.30 - 18.30
- **Thursday, 28 May 2015**: 07.00 - 12.00

Speakers can bring files on CD-Rom or a Memory Stick for uploading into the onsite audiovisual equipment. We ask that all speakers bring their presentations to the speaker ready room the day before their scheduled session, but no later than two hours prior to their scheduled session.

**Welcome Reception**
The Welcome Reception will take place immediately following the Opening Ceremony on Sunday, 24 May 2015 in the Exposition located on the top level of the convention center from 18:00 – 20:30.

**Pre CISTM Courses**
The three pre-CISTM courses are being held on Sunday, 24 May from 13.00 to 17.00 at the Convention Center. If you registered for one of the courses, you would have received your admittance tickets when you registered. If you have any questions, please consult staff at the registration desk.

**CISTM14 Onsite Registration Information**
The Registration Desk is located on the top floor of the convention center near the main entrance. Registration hours are as follows:

- **Sunday, 24 May 2015**: 11.00 - 19.00
- **Monday, 25 May 2015**: 07.00-18.00
- **Tuesday, 26 May 2015**: 07.00 - 18.00
- **Wednesday, 27 May 2015**: 07.00 - 18.00
- **Thursday, 28 May 2015**: 07.30 - 13.00
Maps of Exhibition
and Conference Centre

Convention Centre Floor Plan, Level 2
Maps of Québec Exhibition and Conference Centre, continued

Convention Centre Floor Plan, Level 3
Maps of Québec Exhibition and Conference Centre, continued

Convention Centre Floor Plan, Level 4

Maps of Québec Exhibition and Conference Centre, continued

Convention Centre Floor Plan, Level 4
The ISTM has designated these companies as ISTM Member Service Providers to give ISTM Members considerable and exclusive discounts on the products and services you use every day. When we were developing the program, the ISTM chose to put the entire savings into the ISTM Member discount and is not generating any society revenue or benefit from this program - the savings these companies offer to ISTM Members is reward enough. You can easily identify participating companies by the special ISTM Member Service Provider Logo they are authorized to use.
CISTM14 Opening Ceremony

Québec City Convention Centre

24 May 2015
17.00-18.20

Chairs: David Shlim, ISTM President
        Yen Bui, CISTM14 Local Organizing Committee Chair

17.00 Welcome to Québec City
       Yen Bui, CISTM14 Local Organizing Committee Chair

17.05 Welcome to the CISTM14
       David Shlim, ISTM President

17.15 The CISTM14 Scientific Program
       Leo Visser, CISTM14 Scientific Program Committee Chair

17.25 Guest Speaker
       Dr. Horacio Arruda, Sous-ministre adjoint et Directeur de
       la protection de la santé publique, Ministère de la santé et des
       services sociaux, Québec

17.35 Entertainment: Cocon; Aerial Duo

17.50 Presidential Address
       David Shlim, ISTM President

18.05 Entertainment: Lustrio; Aerial Trio

18.15 Closing Remarks
       Yen Bui, CISTM14 Local Organizing Committee Chair

Welcome Reception to follow.
A membership to ISTM gets you the Membership Advantage Program and special privileges like access to weekly proprietary and important travel alerts from: EpiAlert, HealthMap, iJet and Sitata. All are free to Members, however, iJet and Sitata are ONLY free to ISTM—these alone make membership in the ISTM valuable. Many thanks to the Center for Tropical and travel medicine, Academic Medical Center, The Netherlands for EpiAlert; Boston Children’s Hospital, USA for HealthMap; iJet; and Sitata for their support of the society.

Go to myISTM to see these Alerts.
# CISTM14 Program Schedule

All sessions held in the Centre des Congrès de Québec.

<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.00-17.00</td>
<td><strong>Pre CISTM Course</strong>&lt;br&gt;Pediatric Travel Medicine: what we know, what we think we know and what we actually end up doing!</td>
<td>303AB</td>
</tr>
<tr>
<td></td>
<td><strong>Pre CISTM Course</strong>&lt;br&gt;Expatriates and Lethal Health Threats - Planning, Preparation and Support Learning from Ebola</td>
<td>302AB</td>
</tr>
<tr>
<td></td>
<td><strong>Pre CISTM Course</strong>&lt;br&gt;A Focused Review of Some Topics in Travel Health for Pharmacists</td>
<td>301AB</td>
</tr>
<tr>
<td>16.00-17.00</td>
<td><strong>Nurses’ Reception</strong></td>
<td>Foyer 2</td>
</tr>
<tr>
<td>16.00-17.00</td>
<td><strong>Pharmacists’ Reception</strong></td>
<td>Foyer 3</td>
</tr>
<tr>
<td>17.00-18.20</td>
<td><strong>Opening Ceremony</strong></td>
<td>200ABC</td>
</tr>
<tr>
<td>18.00-20.30</td>
<td><strong>Welcome Reception</strong></td>
<td>Exhibition</td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>MTH1</td>
<td>Meet The History</td>
<td>301AB</td>
</tr>
<tr>
<td>8.00-8.45</td>
<td>History of the Quarantine Station at Grosse Ile</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Marc Desmeules, Canada</td>
<td></td>
</tr>
<tr>
<td>8.00-8.45</td>
<td>CDC Yellow Book</td>
<td>302AB</td>
</tr>
<tr>
<td></td>
<td>Gary Brunette, United States of America</td>
<td></td>
</tr>
<tr>
<td>COD1</td>
<td>Case of the Day</td>
<td>303AB</td>
</tr>
<tr>
<td>8.00-8.45</td>
<td>Pre-Travel</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rogelio Lopez-Velez, Spain</td>
<td></td>
</tr>
<tr>
<td>PL1</td>
<td>Plenary</td>
<td>200ABC</td>
</tr>
<tr>
<td>9.00-10.30</td>
<td>Our Shrinking World: Health in the 21st Century</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: David R. Shlim, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Leo Visser, The Netherlands</td>
<td></td>
</tr>
<tr>
<td></td>
<td>PL1.01 Measuring global health: The global is local [Change your mindset! It's time for a reality check]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Louis Loutan, Switzerland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Outline the most important trends and health challenges in the world using gapminder/health metrics</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Appraise how these changes (global health transitions, global population growth, urbanization, changes in animal helath and human-animal population interactions, and climate change) will influence global migration and travel medicine now and in the future</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Integrate global health concepts into thinking about travel medicine</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------</td>
</tr>
</tbody>
</table>
| Cont.  | **PL1.02 Globalization of infectious diseases. impact of travel on spread of infections**  
        Kamran Khan, Canada                                                                 |          |
|        | • Understand the three consequences of staphylococcal infections by travellers.          |          |
|        | • Learn the role of travellers in the movement of staphylococci and resistance elements across populations. |          |
|        | • Learn the drivers of resistance, including the use of antimicrobials in animals  
      • Recognize how movement of international travellers creates unprecedented opportunities for the emergence of infectious disease outbreaks (H1N1) |          |
|        | • Explain how integration of knowledge of global air traffic patterns and live stream global epidemic intelligence using Bio.Diaspora web application provides valuable insights in where dangerous infectious disease threats are emerging in the world and where they are most likely to spread |          |
|        | • Give examples of how effective and efficient solutions are found by this technology to mitigate the impact of different epidemic and non-epidemic events in the world to health, security and economic activity. |          |
|        | **PL1.03 Global responses to global threats: from risk assessment and surveillance to international health regulations**  
        Martin S. Cetron, United States of America                                                                 |          |
<p>|        | • Outline what the public health responses to the globalization of health challenges are |          |
|        | • Explain how globalization and its health consequences influence travel medicine practice |          |
| 10.30-11.15 | <strong>Morning Break</strong>                                                       | Exhibition |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
</table>
| SY1 11.15-12.45 | **Symposium**
Rabies: Estimating Risks and Optimizing Vaccines  
*Chairs:* Michael Jones, United Kingdom  
Hans Nothdurft, Germany |
|          | **SY1.01** Reducing risks: Efforts in India; Global Rabies Epidemiology  
Jakob Zinsstag, Switzerland |
|          | • Describe the global epidemiology of rabies (animals and humans) and the strategies to reduce risks through mass animal campaigns (e.g. Tchad) |
|          | **SY1.02** Bat contact: When to vaccinate?  
Gaston De Serres, Canada |
|          | • Discuss homology of different lyssaviruses and level of protection of vaccines against different strains |
|          | • Discuss indications for post-exposure prophylaxis after contact with bats (bites, contact with dead bats, presence of bats in room etc.) |
|          | **SY1.03** Rationale for the widespread adoption of multi-site Intradermal Rabies Vaccination  
Mary Warrell, United Kingdom |
<p>|          | • Describe new vaccinations schedules and procedures, discuss level of evidence needed to change policy |</p>
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
</table>
| SY2 11.15-12.45 | **Symposium**  
**Children and Teens on the Move**  
*Chairs:* Louis Loutan, Switzerland  
Karl Neumann, United States of America  
**SY2.01 Health risks and risk perception in teenagers**  
Philip Fischer, United States of America  
• Describe the currently known spectrum of teen travel  
• Discuss teen travel characteristics and analyze their travel health risk perceptions and attitudes  
• Explain some of the most intractable teen travel health risks, including uninhibited sexual activity, and abuse of drugs and alcohol  
• Offer suggestions on how to advise teen travelers in during a pre-travel encounter  
**SY2.02 Young adults - Gap year**  
Mike Starr, Australia  
• Describe the current status of gap year postings: how often, who is most commonly involved, and where people go  
• Discuss the typical characteristics of young adults undertaking a gap year, including their travel health risk perceptions and major health problems  
• Describe the recommendations and requirements for pre- and post-travel assessments  
**SY2.03 Long term expat children**  
Jenny Visser, New Zealand  
• Discuss the medical issues associated with long term expatriate children, including implications on vaccine schedules and management of medical problems during the overseas stay  
• Describe the psychosocial aspects of long-term expatriate travel for children | 200C      |
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
</table>
| 11.15-12.45 | Workshop  Destination: Pacific Islands  
|         | Colleen Lau, Australia  
|         | Peter Leggat, Australia  
|         | Nicholas Zwar, Australia  
|         | • Review common itineraries and places often visited in the region  
|         | • Identify key issues to address in preparing people for travel for the various countries in Oceania  
|         | • Review common health concerns related to travel in the region      | 301AB    |
| 11.15-12.45 | Workshop  Arrive Alive: In Flight Emergencies  
|         | Anna-Maria Carvalho, Canada  
|         | Rui Manuel Correia Pombal, Portugal  
|         | • Outline the physiological basis of aviation medicine  
|         | • Identify medical conditions that represent a contraindication for air travel  
|         | • Discuss the need for in-flight oxygen and the different types of oxygen concentrators  
|         | • Learn to better handle in-flight emergency situations with the use of the emergency medical kit  | 302AB    |
| 11.15-12.45 | Workshop  Stay Awake: Managing Sleep Deprivation, and Jet Lag  
|         | Lee Baker, South Africa  
|         | Jeffery Goad, United States of America  
|         | • Review the physiology of circadian rhythm and the effects of travel on sleep patterns  
|         | • How to best use measures both non-pharmacological and pharmacological (benzodiazepines, zopiclone, melatonin) to alleviate the effects of jet lag  
|         | • Counsel travelers on safety rules and discuss the need for health insurance, including evacuation.  | 303AB    |
| 12.45-14.45 | Lunch available for purchase in Exposition                  | Exhibition |
### Monday, 25 May 2015, continued

<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>SY3</td>
<td>Symposium</td>
<td>200AB</td>
</tr>
<tr>
<td>14.45-16.15</td>
<td><strong>Travelling Coughs and Sneezes: Evolving and Emerging Respiratory Infections</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Chairs:</em> Frank von Sonnenburg, Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Annelies Wilder-Smith, Singapore</td>
<td></td>
</tr>
<tr>
<td>SY3.01</td>
<td><strong>Pigs, chicks and other flus</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Paul Tambyah, Singapore</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Review the epidemiology of influenza virus, the behavior of influenza viruses in tropical countries, and the differences between H1N1 and H7N9</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Discuss the clinical data on influenza infections in tropical countries</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Apply this knowledge to the practice of travel medicine</td>
<td></td>
</tr>
<tr>
<td>SY3.02</td>
<td><strong>MERS CoV</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ziad A Memish, Saudi Arabia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Discuss the epidemiology, origin and mode of transmission of Middle East respiratory syndrome - corona virus</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Review the clinical presentation of Mers-CoV</td>
<td></td>
</tr>
<tr>
<td>SY3.03</td>
<td><strong>Meningococcal: Risk and recommendations [A, B, quadrivalent vaccines]</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Robert C. Read, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Review the epidemiology of invasive meningococcal disease in the world</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Discuss the impact of protein-conjugate polysaccharide vaccines on meningococcal meningitis (including serogroup B)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Relate this knowledge to the practice of travel medicine</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>SY4</td>
<td><strong>Symposium</strong></td>
<td>200C</td>
</tr>
<tr>
<td>14.45-16.15</td>
<td><strong>Providing Care from a Distance: The Role of New Technologies</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Chairs:</em> Lee Baker, South Africa</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ted Lankester, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>SY4.01</td>
<td><strong>Tele-medicine</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Joannes Clerinx, Switzerland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To understand the concept of telemedicine applied to help clinicians solve difficult cases in tropical countries and to assist travellers with health advice when they are sick abroad.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To propose easy solutions for travel clinic to develop telemedicine</td>
<td></td>
</tr>
<tr>
<td>SY4.02</td>
<td><strong>Decision making for evacuation</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jan Von Overbeck, Switzerland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To share long-standing clinical experience of medical care through telephone call center, including red flags</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To present the clinical, financial and legal challenges of telephone call centres, both for pretravel, during trial, and post travel</td>
<td></td>
</tr>
<tr>
<td>SY4.03</td>
<td><strong>Giving advice via email, phone, FB [inc legal issues, regional issues,]</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Eric Johnson, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To present criteria for decision-making around an evacuation in different situations</td>
<td></td>
</tr>
<tr>
<td>WS4</td>
<td><strong>Workshop</strong></td>
<td>301AB</td>
</tr>
<tr>
<td>14.45-16.15</td>
<td><strong>How to get started and do successful Research -</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Designing, Writing, Publishing</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Carolyn Driver, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Davidson Hamer, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To make a status of the involvement of the different professionals into research, being nurses, pharmacists or physicians</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To propose solutions for better integration of all healthcare professionals into research</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• To give the basics for developing a research hypothesis and question, to write a good abstract so that there is good chance to be published in a peer-reviewed journal</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>WS5</td>
<td><strong>Workshop</strong> Schistosomiasis</td>
<td>302AB</td>
</tr>
<tr>
<td>14.45-16.15</td>
<td><strong>Joannes Clerinx,</strong> Belgium</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Eli Schwartz,</strong> Israel</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Examine questions that have emerged regarding treatment of Schistosomiasis including the need for repeat treatment</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Propose approaches to evaluate and treat travellers with possible, probable, and confirmed Schistosomiasis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Recommend strategy for follow up after treatment</td>
<td></td>
</tr>
<tr>
<td>FC1</td>
<td><strong>Free Communication</strong> Altitude and Injuries</td>
<td>303AB</td>
</tr>
<tr>
<td>14.45-16.15</td>
<td><strong>Chairs:</strong> Martin Grobusch, The Netherlands</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Tom Valk,</strong> United States of America</td>
<td></td>
</tr>
<tr>
<td>14.45-15.00</td>
<td><strong>FC1.01 Incidence of illness and injury among visitors to various regions of the world</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Heli Siikamaki,</strong> Finland</td>
<td></td>
</tr>
<tr>
<td>15.00-15.15</td>
<td><strong>FC1.02 Behaviour of Mount Kilimanjaro climbers with serious altitude illness; A pilot study</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Mieke Croughs,</strong> Netherlands</td>
<td></td>
</tr>
<tr>
<td>15.15-15.30</td>
<td><strong>FC1.03 Pulmonary embolism masquerading as high altitude pulmonary edema at high altitude</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Prativa Pandey,</strong> Nepal</td>
<td></td>
</tr>
<tr>
<td>15.30-15.45</td>
<td><strong>FC1.04 Benefit of prostacyclin for severe frostbite at altitude in Nepal</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Ravi Vadlamudi,</strong> Nepal</td>
<td></td>
</tr>
<tr>
<td>15.45-16.00</td>
<td><strong>FC1.05 A two and a half inch leech in the nasopharynx: Live removal using steam</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Sarah Richardson,</strong> United Kingdom</td>
<td></td>
</tr>
<tr>
<td>16.00-16.15</td>
<td><strong>FC1.06 An Update on the Situation in Nepal</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Prativa Pandey,</strong> Nepal</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>----------</td>
<td>--------------------------------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>16.15-17.00</td>
<td>Afternoon Break</td>
<td>Exhibition</td>
</tr>
<tr>
<td>17.00-18.30</td>
<td>Debate</td>
<td>200AB</td>
</tr>
</tbody>
</table>

**Debate**

**Can Malaria Standby Treatment Replace Chemoprophylaxis in Low Risk Areas?**

*Anne McCarthy, Moderator, Canada*

*Paul M. Arguin, United States of America*

*Perry van Genderen, The Netherlands*

*Patricia Schlagenhaus, Switzerland*

- Present the pro and con of chemoprophylaxis, SBET and exposure prevention only for areas with low to moderate endemcity
- Discuss why experts disagree and how to handle these divergent opinions to achieve better harmonization, and hence more coherence and credibility
### Symposium
**Cruise Ship Medicine: It’s More Than Norwalk**

**Chairs:** Richard Dawood, United Kingdom  
Androula Pavli, Greece

#### SY5.01 Health issues on board cruise ships: Epidemiology of illnesses and scope of medical services.

**Grant Tarling, United States of America**

- Number of passengers and crew carried on cruises per year globally
- Review epidemiology of health problems aboard, with particular consideration of host factors (age, health status, etc)
- Briefly describe the scale and scope of the medical services provided by cruise lines

#### SY5.02 Seasickness - When should preventive medicine be discussed?

**Arthur L. Diskin, United States of America**

- Review background and risk assessment for sea sickness
- Discuss prevention and management strategies for sea sickness

#### SY5.03 Best practices - Pre-travel recommendations for cruises

**Eilif Dahl, Norway**

- Discuss legal aspects encountered such as required YF immunization vs. acceptance of exemption certificate
- Describe malaria risk encountered during cruise travel
- Recommend best approaches to prepare travellers particularly with regards to YF
Monday, 25 May 2015, continued

**WS6**
17.00-18.30  
Workshop  
Pre-travel basics and malaria prevention (ABC)  
Anjli Acharya, Canada  
Fiona Genasi, United Kingdom
- Perform a comprehensive individualized risk assessment  
- Give an overview of routine, recommended and required vaccines for travelers, based on age, medical history, destination, type of travel etc.  
- Review the epidemiology of malaria in common destinations (Caribbean, Latin America, South-East Asia, China) and whether antimalarials are needed for these destinations  
- Summarize infectious and non infectious risks related to travel

**WS7**
17.00-18.30  
Workshop  
Running a Travel Clinic in the Impact of Social Media  
Sarah Kohl, United States of America  
Deborah Mills, Australia
- Present ways of using social media (Twitter, Facebook), to make information on travel health issues accessible for our clients  
- Present an example of electronic vaccination card developed at the national level

**FC2**
17.00-18.30  
Free Communication  
Vaccine Preventable Diseases  
Chairs: Pierre Landry Switzerland  
Claire Wong, New Zealand

17.00-17.15  
Measles outbreak associated with international travel, Regina Qu'Appelle Health Region (RQHR), Regina, Saskatchewan, 2014  
Tania Diener, Canada
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.15-17.30</td>
<td>Measles in the 21st century, a continuing preventable risk to travelers: data from the GeoSentinel Network</td>
<td>Mark J. Sotir, United States of America</td>
</tr>
<tr>
<td>17.30-17.45</td>
<td>The safety and tolerability of a combined Hepatitis A and Typhoid vaccine in children aged 2 to 16 years</td>
<td>Colleen Lau, Australia</td>
</tr>
<tr>
<td>17.45-18.00</td>
<td>36-months antibody persistence in children from a JEV endemic region with and without a booster dose of inactivated Japanese Encephalitis Vaccine</td>
<td>Katrin L. Dubischar-Kastner, Austria</td>
</tr>
<tr>
<td>18.00-18.15</td>
<td>Primary vaccination against Japanese Encephalitis leads to age-related differences of humoral and cellular immune responses</td>
<td>Angelika Wagner, Austria</td>
</tr>
<tr>
<td>18.15-18.30</td>
<td>Rabies ONEDAY pre-exposure vaccination: preliminary results from an open-label</td>
<td>Patrick Soentjens, Belgium</td>
</tr>
</tbody>
</table>

Monday, 25 May 2015, continued
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>08.00-08.45</td>
<td><strong>GeoSentinel: The ISTM/CDC Surveillance Network</strong>&lt;br&gt;Davidson Hamer, United States of America</td>
<td></td>
</tr>
<tr>
<td>09.00-10.30</td>
<td><strong>Plenary</strong>&lt;br&gt;The Ins and Outs of Traveller’s Diarrhea&lt;br&gt;Chairs: Lin H. Chen, United States of America&lt;br&gt;Bradley Connor, United States of America</td>
<td>200ABC</td>
</tr>
<tr>
<td>PL2</td>
<td><strong>PL2.01 Human microbiome</strong>&lt;br&gt;Reetta Satokari, Finland&lt;br&gt;• Describe current understanding of human microbiome in health and disease&lt;br&gt;• Explain the interplay of human microbiome with gastrointestinal illness and therapeutic interventions</td>
<td></td>
</tr>
<tr>
<td>PL2</td>
<td><strong>PL2.02 Treat or not to treat/IBS/probiotics</strong>&lt;br&gt;Michael Libman, Canada&lt;br&gt;• Examine the pros and cons of antibiotic therapy for TC with respect to changing microbiome&lt;br&gt;• Discuss post-infectious IBS&lt;br&gt;• Review results on probiotics in preventing and managing TD and PHBS.</td>
<td></td>
</tr>
<tr>
<td>PL2</td>
<td><strong>PL2.03 Antimicrobial resistance</strong>&lt;br&gt;Erika Vlieghe, Belgium&lt;br&gt;• Describe major antimicrobial resistance concerns in GI infections and TD&lt;br&gt;• Propose approaches to travellers with GI infections and TD with focus on geographic variations in antimicrobial resistance</td>
<td></td>
</tr>
<tr>
<td>10.30-11.15</td>
<td><strong>Morning Break</strong>&lt;br&gt;<strong>Poster Tours</strong>&lt;br&gt;Immunizations&lt;br&gt;Bram Goorhuis, Netherlands&lt;br&gt;Returning Travelers&lt;br&gt;Poh Lian Lim, Singapore&lt;br&gt;Special Travelers&lt;br&gt;Maria Mileno, United States of America</td>
<td>Exhibition Meet at Poster Desk</td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>SY6</td>
<td>Symposium</td>
<td>200AB</td>
</tr>
<tr>
<td>11.15-12.45</td>
<td><strong>Communicating Health Risks: Talk the Talk</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Yen Bui, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jane Chiodini, United Kingdom</td>
<td></td>
</tr>
<tr>
<td>SY6.01</td>
<td><strong>Risk perception [cultural differences]</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lorraine Noble, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Understand how people make decisions in order to adapt preventive messages</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Differentiate between types of biases (anchoring, omission etc) that have an influence on decision-making</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Incorporate patients’ values and preferences into the decision-making process</td>
<td></td>
</tr>
<tr>
<td>SY6.02</td>
<td><strong>Communication tools and techniques</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Beth Lown, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Recognize the importance of health literacy in communication: what we say and what travelers actually understand</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Use effective, patient-centered communication strategies to promote travelers’ adherence to preventive measures [Use motivational interview techniques to promote travelers’ adherence to preventive measures]</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Practical tools to help patients make informed decisions</td>
<td></td>
</tr>
<tr>
<td>SY6.03</td>
<td><strong>Impact evaluation of messages</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mieke Croughs, The Netherlands</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review studies evaluating the impact of travel advice</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify factors that hinder the effectiveness of travel advice</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe research methods that could be used to measure effectiveness of travel advice</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>SY7 11.15-12.45</td>
<td><strong>Symposium</strong>&lt;br&gt;Optimizing Migrant Health - The Role of Travel Medicine&lt;br&gt;<em>Chairs:</em> Suzanne Gagnon, Canada&lt;br&gt;Rogelio Lopez-Velez, Spain</td>
<td>200C</td>
</tr>
<tr>
<td>SY7.01</td>
<td><em>What is the intersection between MH and TM?</em>&lt;br&gt;Francesco Castelli, Italy&lt;br&gt;• Recognize the increasing impact of global migration on human health&lt;br&gt;• Outline the different categories of migrants and the breadth of their complex health needs&lt;br&gt;• Identify priority health needs that can be addressed by travel medicine practitioners</td>
<td></td>
</tr>
<tr>
<td>SY7.02</td>
<td><em>Novel strategies to engage VFRs</em>&lt;br&gt;Anita Heywood, Australia&lt;br&gt;• Outline the major health risks of the VFR population&lt;br&gt;• Describe the major barriers to uptake of pre-travel health care and the risk behaviors that lead to increased travel health risks in VFR travellers&lt;br&gt;• Give examples of novel strategies and interventions to engage immigrant communities to improve the health of VFRs travellers</td>
<td></td>
</tr>
<tr>
<td>SY7.03</td>
<td><em>Best practices</em>&lt;br&gt;William Stauffer, United States of America&lt;br&gt;• Describe the most important health issues of the migrant population&lt;br&gt;• List the most important screening tests and health interventions to promote migrant health&lt;br&gt;• Review the most important opportunities to promote health of migrants in the pre-travel setting such as targeted screening and updating routine vaccinations</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>-----------</td>
<td>----------------------------------------------</td>
<td>----------</td>
</tr>
</tbody>
</table>
| WS8       | **Workshop**
           | The Immunocompromised Traveler
           | David O. Freedman, United States of America
           | Cornelia Staehelin Fux, Switzerland
           | Formulate the characteristics of main types of immunosuppression
           | Deduce the most relevant infectious disease risks associated with these main types of immunosuppression
           | Predict the most likely antibody response to primary and secondary vaccinations
           | Discuss the safety and efficacy of live attenuated vaccines in immunosuppressed travellers. | 301AB       |
| WS9       | **Workshop**
           | Rashes on Return Dermatology for the Travel Practitioner
           | Miguel Cabada, Peru
           | Eric Caumes, France
           | Describe cases of travelers presenting with dermatologic findings.
           | Illustrate common travel-related skin problems as well as exotic diagnoses | 302AB       |
| FC3       | **Free Communication**
           | Issues in Malaria
           | Chairs: Charles D. Ericsson, United States of America
           | Lars Rombo, Sweden
           | 11.15-11.30 FC3.01
           | Effectiveness of Twice a week prophylaxis with Atovaquone-proguanil in long-term travelers to Sub-Saharan Africa
           | Eli Schwartz, Israel
           | 11.30-11.45 FC3.02
           | Malaria prevention strategies: A 10-year prospective study in a Swiss travel clinic
<pre><code>       | Rim Boubaker, Switzerland | 303AB       |
</code></pre>
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.45-12.00</td>
<td><strong>FC3.03</strong> Recommendations for malaria prevention in moderate to low risk areas: traveller’s choice and risk perception</td>
<td>FC3.03</td>
</tr>
<tr>
<td></td>
<td>Rachel Voumard, Switzerland</td>
<td></td>
</tr>
<tr>
<td>12.00-12.15</td>
<td><strong>FC3.04</strong> The road to licensure of a highly protective malaria vaccine for travelers based on Whole Plasmodium Falciparum Sporozoites (PfSPZ)</td>
<td>FC3.04</td>
</tr>
<tr>
<td></td>
<td>Thomas L. Richie, United States of America</td>
<td></td>
</tr>
<tr>
<td>12.15-12.30</td>
<td><strong>FC3.05</strong> The clinical development of highly protective malaria vaccines for travelers based on Whole Plasmodium Falciparum Sporozoites (PfSPZ)</td>
<td>FC3.05</td>
</tr>
<tr>
<td></td>
<td>Thomas L. Richie, United States of America</td>
<td></td>
</tr>
<tr>
<td>12.30-12.45</td>
<td><strong>FC3.06</strong> Malaria in travellers returning or migrating to Canada: Surveillance report from CanTravNet Surveillance Data, 2003—2013</td>
<td>FC3.06</td>
</tr>
<tr>
<td></td>
<td>Andrea K. Boggild, Canada</td>
<td></td>
</tr>
<tr>
<td>12.45-14.45</td>
<td>Lunch available for purchase in Exposition</td>
<td>Exhibition</td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>SY8</td>
<td><strong>Symposium</strong></td>
<td>200AB</td>
</tr>
<tr>
<td>14.45-16.15</td>
<td>Can Travel Medicine Recommendations be Evidence Based? Is There Science Behind Our Recommendations or is it All Just Art?</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Chairs:</em> Phyllis Kozarsky, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Edward Ryan, United States of America</td>
<td></td>
</tr>
<tr>
<td>SY8.01</td>
<td>A passing “GRADE” in travel medicine</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Gordon Guyatt,</strong> Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review the most commonly used EBM methods and highlight their strengths and limitations</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe the GRADE process, from reviewing the evidence, balancing risks and benefits, creating thresholds, incorporating values and preference and developing guidelines</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Outline the strengths and weakness of GRADE methodology</td>
<td></td>
</tr>
<tr>
<td>SY8.02</td>
<td><strong>GRADE-ing</strong> typhoid fever vaccination</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Steve Schofield,</strong> Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe the process of GRADE in a travel framework and its strengths and weaknesses</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review the process of using GRADE to produce the CATMAT statement on typhoid vaccine and outline the challenges encountered.</td>
<td></td>
</tr>
<tr>
<td>SY8.03</td>
<td><strong>Yellow fever immunity for ever (single shot)?</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Philippe Duclos,</strong> France</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe how the GRADE methodology was used to produce the single dose WHO Yellow Fever guidelines</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe the challenges encountered using GRADE in this context and its strengths and weaknesses</td>
<td></td>
</tr>
</tbody>
</table>
## Tuesday, 26 May 2015, continued

### SY9
**14.45-16.15**

<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>SY9</td>
<td><strong>Symposium</strong> &lt;br&gt; <strong>In and Out of Africa - Chik, Zik and Dengue</strong> &lt;br&gt; <em>Chairs: Pornthep Chanthavanich, Thailand</em> &lt;br&gt; <em>Gerard Sonder, The Netherlands</em></td>
<td>200C</td>
</tr>
<tr>
<td></td>
<td><strong>SY9.01</strong> &lt;br&gt; <em>The spread of Chikungunya</em> &lt;br&gt; <em>Philippe Parola, France</em>&lt;br&gt; • Describe and explain the spread of Chikungunya in the America’s</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>SY9.02</strong> &lt;br&gt; <em>Dengue in new places</em> &lt;br&gt; <em>Tyler Michael Sharp, Puerto Rico</em>&lt;br&gt; • Describe and explain the spread of Dengue in new places such as Africa (Kenya and Tanzania)</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>SY9.03</strong> &lt;br&gt; <em>Zika</em> &lt;br&gt; <em>Erin Staples, United States of America</em>&lt;br&gt; • Describe and explain the spread of Zika out of Africa</td>
<td></td>
</tr>
</tbody>
</table>

### WS10
**14.45-16.15**

<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>WS10</td>
<td><strong>Workshop</strong> &lt;br&gt; <em>Yellow Fever and Japanese Encephalitis (ABC)</em> &lt;br&gt; <em>Natalie Gray, Australia</em> &lt;br&gt; <em>Susan Kuhn, Canada</em>&lt;br&gt; • Formulate the main characteristics of the yellow fever vaccine&lt;br&gt; • Evaluate the evidence for long-lasting protective immunity&lt;br&gt; • Assess the risk of yellow fever and risk of severe adverse events&lt;br&gt; • Translate risk-benefit considerations into individualized travel advice</td>
<td>301AB</td>
</tr>
</tbody>
</table>

### WS11
**14.45-16.15**

<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>WS11</td>
<td><strong>Workshop</strong> &lt;br&gt; <em>TB and Travel - What Are the Risks and When and How to Screen</em> &lt;br&gt; <em>Martin Grobusch, The Netherlands</em> &lt;br&gt; <em>Kevin Schwartzman, Canada</em>&lt;br&gt; • Review the risk of TB in travellers and review the epidemiology of drug sensitive and drug resistant.&lt;br&gt; • List the different tests for LTBI including the TST and IGRA and their strengths and weaknesses&lt;br&gt; • Describe when and how to use the TST and the IGRA in the pre and post travel settings.</td>
<td>302AB</td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>-------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>FC4</td>
<td><strong>Free Communication</strong></td>
<td>303AB</td>
</tr>
</tbody>
</table>
| 14.45-16.15| **Gut Bugs, Tough Bugs**  
*Chairs:* Effrossyni Gkrania-Klotsas, United Kingdom  
Mary-Louise Scully, United States of America |          |
| 14.45-15.00| **FC4.01** Undesired travel souvenirs - Incidence and causes of traveler’s diarrhea in Dutch travelers using cytotoxic drugs and/or monoclonal antibodies and in their travel companions after travel to the (sub)tropics  
Jessica A. Vlot, Netherlands |          |
| 15.00-15.15| **FC4.02** Acquisition of cephalosporin- and colistin-resistant salmonella enterica by pilgrims during the 2013 Hajj  
Philippe Gautret, France |          |
| 15.15-15.30| **FC4.03** Antibiotic sensitivity pattern in enteric fever patients presenting at CIWEC Hospital  
Rashila Pradhan, Nepal |          |
| 15.30-15.45| **FC4.04** Increasing resistance in diarrheal pathogens among travelers to Nepal  
Prativa Pandey, Nepal |          |
| 15.45-16.00| **FC4.05** Long-term follow-up of schistosomiasis infection in Belgian Military personnel returning  
Patrick Soentjens, Belgium |          |
| 16.00-16.15| **FC4.06** Risk of contracting Multiresistant (ESBL) Escherichia coli increases if traveler’s diarrhea is treated with antibiotics (not loperamide)  
Anu Kantele, Finland |          |
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>16.15-17.00</td>
<td><strong>Afternoon Break</strong></td>
<td>Exhibition Meet at Poster Desk</td>
</tr>
<tr>
<td></td>
<td><strong>Poster Tours</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Immunizations</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Martin Haditsch</em>, Austria</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Pre-travel</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Edward Ryan</em>, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Vector Borne Diseases</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Philippe Gautret</em>, France</td>
<td></td>
</tr>
<tr>
<td>17.00-18.30</td>
<td><strong>Panel</strong></td>
<td><strong>Challenging Cases: Tropical Diseases in Returned Travellers and Migrants</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Panel</strong></td>
<td><strong>200AB</strong></td>
</tr>
<tr>
<td></td>
<td><em>Andrea K. Boggild</em>, Moderator, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Christina M. Coyle</em>, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Jakob Cramer</em>, Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Marc Mendelson</em>, South Africa</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe clinical approach to ill travellers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Apply testing strategies that can aid in confirming diagnoses in ill travellers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss differential diagnoses of common presenting syndromes</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>SY10</td>
<td><strong>Symposium</strong>&lt;br&gt;Working Abroad: Keeping Safe and Sane Before, During and After Travel&lt;br&gt;<em>Chairs: Masatoki Adachi, Japan&lt;br&gt;Kenneth Dardick, United States of America</em></td>
<td>200C</td>
</tr>
<tr>
<td>17.00-18.30</td>
<td><strong>SY10.01 Preparing for challenging environments</strong>&lt;br&gt;Dipti Patel, United Kingdom&lt;br&gt;- Evaluation of health hazards in international setting&lt;br&gt;- Fulfilling duty of care through implementing measures to mitigate against identified risks to international workers&lt;br&gt;- Relative merits of health &amp; safety legislation in the country of the sending agency as opposed to that of the country where the assignment is being carried out&lt;br&gt;- Consideration of the legal, ethical and moral obligations to deployed workers including those with disabilities, and Consideration of reasonable adjustments for disabled workers.</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>SY10.02 Correspondent; Hostile environments [During]</strong>&lt;br&gt;Oliver Morton, United Kingdom&lt;br&gt;- Determining an acceptable level of risk in intrinsically unsafe environments&lt;br&gt;- Remote advice &amp; support including emergency response during assignment to sustain workers in the field&lt;br&gt;- Factors influencing the resilience and effectiveness of workers in the field&lt;br&gt;- Managing the different needs &amp; expectations of expatriate and national workers</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>SY10.03 Debriefing and psychological health</strong>&lt;br&gt;Simon Clift, United Kingdom&lt;br&gt;- Appropriate management post-assignment&lt;br&gt;- Identifying and treating psychological trauma&lt;br&gt;- Mitigation measures to build mental resilience&lt;br&gt;- Consideration of reasonable adjustments for disabled workers.</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td><strong>Tuesday, 26 May 2013, continued</strong></td>
<td></td>
<td>301AB</td>
</tr>
<tr>
<td><strong>WS12</strong></td>
<td>Workshop&lt;br&gt;Be Prepared: What to Put in Your Travel Medicine Kit (ABC)&lt;br&gt;Professor Larry Goodyer, United Kingdom&lt;br&gt;Caroline Zeind, United States of America&lt;br&gt;- Describe medications/products needed for personal protection of the traveler&lt;br&gt;- Discuss medications recommended for self-management of illness by the traveler</td>
<td><strong>WS12</strong></td>
</tr>
<tr>
<td>17.00-18.30</td>
<td></td>
<td><strong>WS13</strong></td>
</tr>
<tr>
<td><strong>WS13</strong></td>
<td>Workshop&lt;br&gt;Extreme Weather Travel&lt;br&gt;Michael Jones, United Kingdom&lt;br&gt;Christopher Van Tilburg, United States of America&lt;br&gt;- Recognize the various clinical manifestations and danger signs that can arise during exposure to extreme cold and heat&lt;br&gt;- Formulate preventive measures to prevent disease from exposure to extreme cold and heat</td>
<td><strong>WS13</strong></td>
</tr>
<tr>
<td>17.00-18.30</td>
<td></td>
<td>303AB</td>
</tr>
<tr>
<td><strong>FC5</strong></td>
<td>Free Communication&lt;br&gt;Pre-travel Issues&lt;br&gt;Chairs: Garth Brink, South Africa&lt;br&gt;Jeff Goad, United States of America</td>
<td><strong>FC5</strong></td>
</tr>
<tr>
<td>17.00-17.15</td>
<td>Development and usage of internet tools to improve travelers’ health: Pre-travel PREP and TRhIP&lt;br&gt;Regina LaRocque, United States of America</td>
<td><strong>FC5.01</strong></td>
</tr>
<tr>
<td>17.15-17.30</td>
<td>Emotional drive of providing health promotion by digital animation to international visitors in Japan&lt;br&gt;Mariko Nishikawa, Japan</td>
<td><strong>FC5.02</strong></td>
</tr>
<tr>
<td>17.30-17.45</td>
<td>Improving the CDC Yellow Book with country-specific Yellow Fever maps&lt;br&gt;R. Ryan Lash, United States of America</td>
<td><strong>FC5.03</strong></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------------------------------</td>
</tr>
<tr>
<td>17.45-18.00</td>
<td>Mass gatherings: Health risks during the FIFA World Cup 2014</td>
<td>Kirsten A. Eberhardt, Germany</td>
</tr>
<tr>
<td>18.00-18.15</td>
<td>Travellers’ profile and travel clinic vaccine practices: A 10-year prospective study in Switzerland</td>
<td>Rim Boubaker, Switzerland</td>
</tr>
<tr>
<td>18.15-18.30</td>
<td>How Did Travellers in Endemic Countries Use Rapid Diagnostic Tests for Malaria Provided by a Travel-clinic? A Cohort Study</td>
<td>Delphine Berthod, Switzerland</td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------------------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>MTH2</td>
<td>Meet the History: Foundation of the Hospital in Quebec City in Response to Large Epidemics and Immigration in the 19th Century</td>
<td>301AB</td>
</tr>
<tr>
<td>08.00-08.45</td>
<td>Dr. Marc Desmeules, Canada</td>
<td></td>
</tr>
<tr>
<td>COD2</td>
<td>Case of the Day: Essentials and pitfalls of post-exposure rabies vaccination after dog/monkey bite abroad (with reflections on simian herpes B and empiric antibiotic coverage)</td>
<td>303AB</td>
</tr>
<tr>
<td>08.00-08.45</td>
<td>Andreas Neumayr, Switzerland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Management of vivax malaria in returning-travellers/migrants (with reflections on non-chloroquine regimen and its impact on consecutive primaquine therapy + genetic polymorphisms impacting primaquine efficacy)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Acute schistosomiasis presenting with repeated fever episodes in a traveller returning from Madagascar (emphasis on exposure history taking and differential diagnosis of fever + eosinophilia)</td>
<td></td>
</tr>
<tr>
<td>08.00-08.45</td>
<td>Professional Development Session on Writing Abstracts: Gotta Get Published</td>
<td>302AB</td>
</tr>
<tr>
<td></td>
<td>Charles D. Ericsson, United States of America</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>--------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>----------</td>
</tr>
</tbody>
</table>
| PL3    | **09.00-10.30**  
**Plenary** Vaccinations: What’s New, Who to Target and How to Get Shots Delivered  
*Chairs: Christina Greenaway, Canada  
Marc Mendelson, South Africa* | 200ABC   |
|        | **PL3.01 Vaccine pipeline: From innovation to issues of shortages**  
Brian Ward, Canada  
- Review the process of vaccine production, from antigen discovery, vaccine production to vaccine distribution  
- Review examples of important new travel vaccines on the horizon  
- Describe strategies to optimize vaccine production and distribution  
- List the most important reasons for interruption of vaccine supply and vaccine shortages |          |
|        | **PL3.02 Dengue: From innovation to first vaccine**  
Annelies Wilder-Smith, Singapore  
- Discuss the challenges in developing dengue vaccines and review the different dengue vaccines candidates  
- Review the clinical efficacy data for dengue vaccines  
- Discuss the role of vaccines in the prevention of dengue in endemic populations and travellers. |          |
|        | **PL3.03 Vaccine refusal: How to get around it**  
Regina LaRocque, United States of America  
- Review the barriers to uptake of vaccine and the key reasons causes of vaccine refusal  
- Review strategies to improve vaccine uptake and to address the issues and concerns raised by the antivaccination movement.  
- Describe and provide key examples of the antivaccination movement and on how this has impacted on vaccine refusal and disease control. |          |
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
</table>
| Cont.   | **PL3.04** Vaccination in immunosuppressed: Does it work/is it safe/how to find out  
Camille Nelson Kotton, United States of America  
- Review the different types of immunosuppression medications and immunosuppressive diseases.  
- Describe the increased risk of travel-related diseases in the immunosuppressed host  
- Outline the implications for response to vaccines and review vaccine efficacy and safety in this population  
- Review recommendations for vaccinations in immunosuppressed travellers |          |
| 10.30-11.15 | **Morning Break** |         |
| SY11 11.15-12.45 | **Symposium**  
What's the Buzz: Current Issues in Malaria  
*Chairs:* Santanu Chatterjee, India  
Alan Magill, United States of America  
**SY11.01** Biomarkers in Malaria  
Andrea L. Conroy, Canada  
- Explain the pathophysiological hypotheses that led to the discovery of new host biomarkers. Describe their accuracy to predict death in severe malaria and their potential usefulness in medical practice.  
**SY11.02** Zoonotic Malaria (P Knowlesi)  
Balbir Singh, Malaysia  
- Describe the epidemiology of zoonotic Malaria and its potential threat for humans (knowlesi, amazoniensis). Discuss the clinical picture, performance of different diagnostic tests and efficacy of treatment for P knowlesi.  
**SY11.03** Updates on Vivax; Resistance  
Nicholas Day, Thailand  
- Explain the pathophysiology of P vivax malaria and the observed clinical picture  
- Describe the level of resistance of P vivax to the different antimalarial drugs and its geographical distribution  
- Describe the epidemiology, clinical spectrum and pathophysiology of P vivax malaria, prevention of relapse and the extent of drug resistance in P vivax | 200AB    |
<table>
<thead>
<tr>
<th>Time</th>
<th>Program</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>WS14</td>
<td><strong>Workshop</strong></td>
<td>200C</td>
</tr>
<tr>
<td>11.15-12.45</td>
<td><strong>Travelling at Altitude (ABC)</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Prativa Pandey</strong>, Nepal</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>David Shlim</strong>, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- At the end of the session, participants will be familiar with the risk of altitude illness in a number of different scenarios, and how to recommend preventive strategies. They will know how altitude illness progresses to its severe forms, and how to prevent death from altitude illness. They will also become familiar with the differential diagnosis of altitude illness, and how to evaluate a patient who has descended with possible altitude illness.</td>
<td></td>
</tr>
<tr>
<td>WS15</td>
<td><strong>Workshop</strong></td>
<td>301AB</td>
</tr>
<tr>
<td>11.15-12.45</td>
<td><strong>Destination: Ethiopia</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Nancy Piper Jenks</strong>, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Makeda Semret</strong>, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Review the key historical and cultural aspects of the Ethiopian population</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Review common itineraries and places often visited in the region</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Review common health concerns related to travel in the region</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Identify key issues to address in preparing people for travel with specific mention of yellow fever and malaria</td>
<td></td>
</tr>
<tr>
<td>WS16</td>
<td><strong>Workshop</strong></td>
<td>302AB</td>
</tr>
<tr>
<td>11.15-12.45</td>
<td><strong>Travelling with Chronic Medical Conditions</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Mary-Louise Scully</strong>, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Fons Van Gompel</strong>, Belgium</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Review the issues of managing diabetes while travelling including the use of portable glucometers and adjusting medication with erratic travel schedule</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Review the issues related to managing anticoagulants during travel including the use of portable INR machines</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Review management issues related to sleep apnea and the use of CPAP during travel</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>----------</td>
<td>---------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>11.15-12.45</td>
<td><strong>Workshop</strong> Screening Migrants - Evidence and Best Practices</td>
<td>WS17 303AB</td>
</tr>
<tr>
<td></td>
<td>Elizabeth D. Barnett, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rogelio Lopez-Velez, Spain</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review the most important health conditions in the migrant population</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• List the most important screening test and interventions for health promotion in the migrant population</td>
<td></td>
</tr>
<tr>
<td>12.45-14.45</td>
<td><strong>Lunch</strong></td>
<td>Exhibition</td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>--------</td>
<td>----------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>SY12</td>
<td>Symposium</td>
<td>200AB</td>
</tr>
<tr>
<td>14.45-16.15</td>
<td>Tourism Outside of the Box</td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Chairs:</em> Davidson Hamer, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Peter Leggat, Australia</td>
<td></td>
</tr>
<tr>
<td>SY12.01</td>
<td>Ecotourism: Walking the walk, not just talking the talk</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Bjorn Heyerdahl, South Africa</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Appraise ecotourism - the psychology and travel preparedness of nature-based tourists</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Formulate how to sustain environment</td>
<td></td>
</tr>
<tr>
<td>SY12.02</td>
<td>Voluntourism</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sheila Hall, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Outline the concept of voluntourism and the profile of the voluntourist</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review organizations that address potential problems and promote best practices in volunteering</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss common health pitfalls and psychological stress due to poor cultural adaptation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Formulate practical and appropriate advice to promote tips to better understanding of interactions between volunteer and host communities</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Illustrate the core issues of benefit and harm, idealism and ethics</td>
<td></td>
</tr>
<tr>
<td>SY12.03</td>
<td>Cross border healthcare and medical tourism</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jill Hodges, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Outline the nature, extent and future trends of the global medical tourism industry</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Explain the different motivations for seeking cross border health care</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss the potential advantages, downsides, and ethical and legal challenges in medical tourism</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review the responsibility as pre-travel advisers to this group of travellers</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>------------</td>
<td>-----------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>WS18</td>
<td>Workshop</td>
<td>200C</td>
</tr>
<tr>
<td>14.45-16.15</td>
<td>What's New: Top Papers in Travel Medicine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Elizabeth Talbot, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Joseph Torresi, Australia</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review papers from the past 1-2 years that have significant impact on the practice of travel medicine</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Appraise findings of the papers on whether they support current practice or indicate the need for change</td>
<td></td>
</tr>
<tr>
<td>WS19</td>
<td>Workshop</td>
<td>301AB</td>
</tr>
<tr>
<td>14.45-16.15</td>
<td>Pregnant and Pediatric Travellers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sheila Mackell, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Claire Wong, New Zealand</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Identify key issues to address in preparing children for travel</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review common questions and concerns related to travel during pregnancy</td>
<td></td>
</tr>
<tr>
<td>SY13</td>
<td>Symposium</td>
<td>302AB</td>
</tr>
<tr>
<td>14.45-16.15</td>
<td>Making the Diagnosis: New Tools and How to Use Them</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Martin Haditsch, Austria</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alfons von Gompel, Belgium</td>
<td></td>
</tr>
<tr>
<td>SY13.01</td>
<td>New non-malarial rapid diagnostic tests (i.e. leptospirosis, brucella, dengue etc.)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cedric Yansouni, Canada</td>
<td></td>
</tr>
<tr>
<td>SY13.02</td>
<td>New parasite diagnostic tests</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lisette van Lieshout, The Netherlands</td>
<td></td>
</tr>
<tr>
<td>SY13.03</td>
<td>Choosing diagnostic tests for different clinical syndromes</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jay Keystone, Canada</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review the most important diagnostic tests to order and their interpretation for determining the etiology of fever in the returned traveller</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review the most important diagnostic tests to order and their interpretation for respiratory symptoms in the returned traveller</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Review the most important diagnostic tests to order and their interpretation for eosinophilia in the returned traveller</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>-----------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>FC6</td>
<td><strong>Free Communication</strong></td>
<td>303AB</td>
</tr>
<tr>
<td>14.45-16.15</td>
<td><strong>Health Problems in Returning Travellers</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em>Chairs:</em> Clive Brown, United States of America, Herbert DuPont, United States of America</td>
<td></td>
</tr>
<tr>
<td>14.45-15.00</td>
<td><strong>FC6.01</strong> Discovering the spectrum of emerging viral pathogens in returned febrile travellers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ruwandi Kariyawasam, Canada</td>
<td></td>
</tr>
<tr>
<td>15.00-15.15</td>
<td><strong>FC6.02</strong> Seroprevalence of and seroconversion to Hepatitis E Virus IgG Antibody among individuals evaluated by the Boston Area Travel Medicine Network before and after travel, 2009-2010</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Kira A. Barbre, United States of America</td>
<td></td>
</tr>
<tr>
<td>15.15-15.30</td>
<td><strong>FC6.03</strong> Chikungunya and Dengue Virus infections among United States community service volunteers returning from the Dominican Republic, 2014</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alexander J. Millman, United States of America</td>
<td></td>
</tr>
<tr>
<td>15.30-15.45</td>
<td><strong>FC6.04</strong> Dengue Virus infections: Incidence among long term travelers</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Femke W. Overbosch, Netherlands</td>
<td></td>
</tr>
<tr>
<td>15.45-16.00</td>
<td><strong>FC6.05</strong> The health of the Peace Corps volunteer</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Susan J. Henderson, United States of America</td>
<td></td>
</tr>
<tr>
<td>16.00-16.15</td>
<td><strong>FC6.06</strong> Travel related health risks in moderate and severe immunocompromised patients: A case-control study</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Souad Dekkiche, Switzerland</td>
<td></td>
</tr>
<tr>
<td>16.15-17.15</td>
<td><strong>Afternoon Break</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Poster Session</strong></td>
<td></td>
</tr>
<tr>
<td>17.15-18.45</td>
<td><strong>ISTM Membership Assembly</strong></td>
<td>200C</td>
</tr>
<tr>
<td>18.45-19.30</td>
<td><strong>Cocktail Reception for ISTM Members</strong></td>
<td>200C</td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>MTH3</td>
<td><strong>Meet the History</strong></td>
<td>301AB</td>
</tr>
<tr>
<td>08.00-08.45</td>
<td><strong>Epidemic louse-borne typhus among immigrants to Québec in 1847-1848</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Réjean Dion, Canada</td>
<td></td>
</tr>
<tr>
<td>HC1</td>
<td><strong>Highlights of the Conference</strong></td>
<td>301AB</td>
</tr>
<tr>
<td>08.00-08.45</td>
<td>Gerard Flaherty</td>
<td></td>
</tr>
<tr>
<td>PL4</td>
<td><strong>Plenary</strong></td>
<td>200AB</td>
</tr>
<tr>
<td>09.00-10.30</td>
<td><strong>Malaria: New Challenges and Opportunities</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Fiona Genasi, United Kingdom Karin Leder, Australia</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>PL4.01 Malaria elimination and eradication: hopes, challenges and barriers</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Alan Magill, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe the progresses that have been made towards malaria control and their main facilitators</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Highlight the major current and future obstacles, including species-specific factors that hinder control efforts</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe new factors that are hindering use of certain drugs and changes in drug susceptibility</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe the role of vaccine development in malaria control</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss how historical lessons can guide the future fight</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>PL4.02 Poor quality medicines and artemisinin resistance</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Paul Newton, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe the magnitude of the problem of poor quality antimalarials and its geographical variability</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Discuss the impact of poor quality medicines on drug resistance, including the emerging problem of artemisinin resistance</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>PL4.03 Achieving consensus on malaria recommendations: Is it possible?</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mary Elizabeth Wilson, United States of America</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Describe the range of approaches for malaria prophylaxis</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Explain why the interpretation and weighting given to the data used in many national varies, including historical, cultural and political reasons for the differences in approaches</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Suggest how processes might be standardised for policy development, and consider specific management issues for which harmonization may be achievable</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Program</td>
<td>Location</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------</td>
<td>----------</td>
</tr>
<tr>
<td>10.30-10.45</td>
<td>Morning Break</td>
<td>200C</td>
</tr>
<tr>
<td>LBP1</td>
<td>Late Breaker Plenary</td>
<td>200AB</td>
</tr>
<tr>
<td>10.45-12.15</td>
<td>Ebola</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chairs: Blaise Genton, Switzerland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Robert Steffen, Switzerland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LBP1.01 The Epidemiology of the West African Ebola outbreak and control measures used</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Joann Liu, Switzerland</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LBP1.02 New therapies for Ebola Virus- medications and vaccines</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Speaker to be determined</td>
<td></td>
</tr>
<tr>
<td></td>
<td>LB1.03 Approach to the work up of returned traveller with suspected hemorrhagic fever</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Daniel Bausch, United States of America</td>
<td></td>
</tr>
<tr>
<td>12.00-12.30</td>
<td>Closing Ceremony</td>
<td>200AB</td>
</tr>
</tbody>
</table>
Posters

Altitude, Diving and Other Environmental Exposures

**PO01.01**
Efficacy of Ipomea pes-caprae Ointment as an Add-on Therapy in Patient with Jellyfish Dermatitis
W. Piyaphanee¹, V. Choovichian¹, W. Matsee², K. Palakul³, J. Olanwijitwong², N. Chinnarat², T. Chaiyakul⁴
¹Mahidol University, Department of Clinical Tropical Medicine, Bangkok, Thailand, ²Mahidol University, Hospital for Tropical Diseases, Bangkok, Thailand, ³Mahidol University, Department of Medical Entomology, Bangkok, Thailand, ⁴Royal Thai Navy, Naval Medical Department, Bangkok, Thailand

**PO01.02**
Analysis of the Quality of Web-based Pre-travel Health Advice for Prospective Travellers to High Altitude
M. Javaherian¹, G. Flaherty¹,²
¹National University of Ireland, School of Medicine, Galway, Ireland, ²International Medical University, Kuala Lumpur, Malaysia

**PO01.03**
Emergency Medical Management of Air Embolism & Arterial Gas Embolism in SCUBA Divers
G. Schroeder
American Academy of Urgent Care Medicine, Executive Council, Orlando, United States

Enteric Infections

**PO02.01**
A Placebo Controlled Pilot Study of Dietary Nitrate as Beetroot Juice, in the Prevention of Traveller’s Diarrhoea
J. Cruise⁴, P.J. Hennis², B. Carroll³, D.S. Martin², R.H. Behrens¹,³
¹London School of Hygiene & Tropical Medicine, Department of Clinical Research, London, United Kingdom, ²UCLH NIHR Biomedical Research Centre, Institute of Sport and Exercise Health, Centre for Altitude Space and Extreme Environment Medicine, London, United Kingdom, ³Hospital for Tropical Diseases, Travel Clinic, London, United Kingdom
Norovirus Outbreak at a Resort Hotel - United States Virgin Islands, 2012
U.S. Center of Disease Control, Atlanta, United States

Enteric Fever in 3 Vaccinated Portuguese Travelers Returning from India
R.V. Ferraz, C. Abreu, N.R. Pereira, R. Duro, A.S. Pinto, C. Carvalho1, J. Nuak, C. Caldas, A. Sarmento
School of Medicine - São João’s Hospital, Infectious Diseases, Porto, Portugal

Phenotypic Characterization of Enterotoxigenic Escherichia coli (ETEC) Isolates Obtained from International Travelers with Diarrhea to India and Latin America and a Pediatric Population from USA
Z.-D. Jiang1, V. Kahart1, H.L. Du Pont1, R. Steffen2
1University of Texas Health Science Center, Houston, United States, 2University of Zurich, Zurich, Switzerland

Use of a Bioactive Polyphenol Solution to Treat Acute Infectious Diarrhea in Adults
T. Lawson
Lawson & Associates, El Cerrito, United States

Disseminated Strongyloidiasis Successfully Treated with Parenteral Ivermectine
C. Ficko1, M. Gominet1, L. Mangouka1, A. Cremades1, D. Delaune2, O. Aoun1, S. Cremades3, P. Pasquier4, C. Rapp5
1HIA Bégin, Infectious Diseases, Saint-Mande Cedex, France, 2HIA Bégin, Biology, Saint-Mande Cedex, France, 3HIA Bégin, Medicine, Saint-Mande Cedex, France, 4HIA Bégin, Intensive Care Medicine, Saint-Mande Cedex, France, 5SMIT Bégin, Saint-Mande Cedex, France

A Diarrhea Outbreak Caused by Norovirus at Sea Aboard a Foreign Passenger Cruise Ship
P. Juan
Tianjin International Travel Health Care Center, Tianjin, China
Immunizations (YF, JEV, Rabies, Others)

PO03.01
Safety Analysis of Chinese-produced Quadrivalent Meningococcal Polysaccharide Vaccine
M. He, W. Wang, L. Hua
Shanghai International Travel Healthcare Center, Shanghai, China

PO03.02
Immunogenicity of Booster Doses of the Inactivated Polio Vaccine among Japanese Adult Travelers
S. Fukushima1, T. Nakano2, H. Shimizu3, A. Hamada1
1Tokyo Medical University Hospital, Travellers’ Medical Center, Tokyo, Japan, 2Kawasaki Medical University, Department of Pediatrics, Okayama, Japan, 3National Institute of Infectious Diseases, Department of Virology II, Tokyo, Japan

PO03.03
Determining Immune Responses to Japanese Encephalitis Vaccination - Comparison of Three Different Serological Methods
E.O. Erra1,2, E. Huhtamo1, S. Vene3, H.H. Askling4, L. Lindquist4, L. Rombo4,5, S. Yoksan6, O. Vapalahti1, A. Kantele1,2
1Haartman Institute, Faculty of Medicine, University of Helsinki, Helsinki, Finland, 2Inflammation Center, Clinic of Infectious Diseases, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, 3Public Health Agency of Sweden, Stockholm, Sweden, 4Karolinska Institutet, Department of Medicine, Unit for Infectious Diseases, Stockholm, Sweden, 5Centre for Clinical Research, Sörmland County Council, Eskilstuna, Sweden, 6Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand

PO03.04
Rabies Post-exposure Prophylactic Vaccination for Japanese Travelers
K. Yamamoto1, M. Ujiie1, A. Noguchi2, Y. Kato1, S. Takeuchi1, K. Shinohara3, T. Matono3, H. Uemura3, Y. Fujiya1, M. Mawatari1, S. Kutsuna1, N. Takeshita1, K. Hayakawa1, S. Kanagawa1, S. Inoue2, S. Morikawa2, N. Ohmagari1
1National Center for Global Health and Medicine, Disease Control and Prevention Center / Travel Clinic, Tokyo, Japan, 2National Institute of Infectious Diseases, Department of Veterinary Science, Tokyo, Japan, 3National Center for Global Health and Medicine, Division of Infectious Diseases, Tokyo, Japan
Accelerated 1-Week Vaccination Regimens for Rabies Pre-Exposure and Japanese Encephalitis Prophylaxis


¹The Berlin Center for Travel and Tropical Medicine, Berlin, Germany, ²Bernhard-Nocht Institute for Tropical Medicine, Hamburg, Germany, ³Institute of Tropical Medicine and International Health at Charité, Berlin, Germany, ⁴Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Zurich, Switzerland, ⁵Institute of Specific Prophylaxis and Tropical Medicine, Medical University of Vienna, Vienna, Austria, ⁶University of Munich, Department of Infectious Diseases and Tropical Medicine, Munich, Germany, ⁷Rostock University Medical Center, Department of Tropical Medicine and Infectious Diseases, Rostock, Germany, ⁸Novartis Vaccines and Diagnostics Srl., Siena, Italy, ⁹Novartis Vaccines and Diagnostics AG GmbH, Holzkirchen, Germany, ¹⁰Novartis Vaccines and Diagnostics, Hyderabad, India

Intradermal Preexposure Rabies Vaccination: A 6-year Experience in a Canadian Travel Clinic

S. Barkati¹,², G. Laplante², J.-A. Hudon Duchesne², J. Vincelette¹,²

¹Centre Hospitalier de l’Université de Montréal (CHUM)-Hôpital St-Luc, Microbiologie Médicale et Infectiologie, Montréal, Canada, ²Clinique Santé-Voyage de la Fondation du CHUM, Montréal, Canada

Rapid Responses to Two Bivalent Virus-like Particle Norovirus Vaccine Candidate Formulations in Healthy Adults

F. Baehner, J.P. Cramer, P. Mendelman, NOR-201 Study Group

Takeda Pharmaceutical International GmbH, Zurich, Switzerland

Development of Takeda Vaccine’s Candidate Norovirus VLP Vaccine

R. Bargatze¹, C. Richardson¹, P. Mendelman¹, F. Baehner², A. Borkowski², R. Goodwin¹

¹Takeda Vaccines Inc., Bozeman, United States, ²Takeda Pharmaceutical International GmbH, Zurich, Switzerland
Posters, continued

PO03.09
Vaccination Against Seasonal Influenza Has No Significant Influence on Expected Decrease in Absence from Work Due to Acute Respiratory Tract Diseases
M. Jędras, M. Plebanek, M. Skowrońska, A. Detyniecka
MFA Poland, Foreign Service Medical Centre, Warsaw, Poland

PO03.10
Long Term Immunity 6 Years after Booster Vaccination against Japanese Encephalitis
M. Paulke-Korinek1, H. Kollaritsch1, M. Kundi2, I. Zwazl1, C. Seidl-Friedrich1, T. Jelinek2
1Medical University Vienna, Department of Specific Prophylaxis and Tropical Medicine, Vienna, Austria,
2Medical University Vienna, Institute of Environmental Health, Center for Public Health, Vienna, Austria,
3Berlin Center for Travel and Tropical Medicine, Berlin, Germany

PO03.11
Single Visit Intradermal Rabies Vaccination is Immunogenic
E.F.F. Jonker, L.G. Visser
Leiden University Medical Center, Infectious Diseases C5-P, Leiden, Netherlands

PO03.12
Intradermal Meningococcal Vaccination (MEN-ACYW135)
E.F.F. Jonker1, G.A.M. Berbers2, L.G. Visser1
1Leiden University Medical Center, Infectious Diseases C5-P, Leiden, Netherlands,
2National Institute for Public Health and the Environment (RIVM), Laboratory for Infectious Diseases and Perinatal Screening, Bilthoven, Netherlands

PO03.13
Update on Takeda's Live Attenuated Tetravalent Dengue Vaccine (TDV) Candidate
D. Wallace
Takeda Vaccines Inc., Singapore, Singapore
Influenza Vaccine and Respiratory Illnesses before and after the 2009 Pandemic


1 National Centre for Immunisation Research and Surveillance, Westmead, Australia, 2 King Abdulaziz University, Faculty of Medicine in Rabigh, Department of Family and Community Medicine, Jeddah, Saudi Arabia, 3 Umm Al-Qura University, Makkah, Saudi Arabia, 4 Ministry of Health, Jeddah, Saudi Arabia, 5 King Abdullah Medical City, Makkah, Saudi Arabia, 6 Majmaah University, Faculty of Medicine, Majmaah, Saudi Arabia, 7 Alfaisal University, College of Medicine, Riyadh, Saudi Arabia, 8 Hamad Medical Corporation, Doha, Qatar, 9 Health Protection Agency, London, United Kingdom, 10 Umm Al-Qura University, The Custodian of the two Holy Mosques Institute for Hajj and Umrah Research, Makkah, Saudi Arabia, 11 Centre for Perinatal Infection Research, The Children's Hospital at Westmead and The University of Sydney, Sydney, Australia, 12 Marie Bashir Institute for Infectious Diseases and Biosecurity Institute (MBI), University of Sydney, Sydney, Australia, 13 Menzies Research Institute Tasmania, Hobart, Australia

Characterization of an Age-response Relationship to GSK’s Recombinant Hepatitis B Vaccine in Healthy Adults: An Integrated Analysis

O. Van Der Meeren, P. Crasta, B. Cheuvart, M. De Ridder

1 GSK Vaccines, Wavre, Belgium, 2 GSK Pharmaceutical Ltd., Mumbai, India, 3 Université Libre de Bruxelles, Brussels, Belgium

No Evidence that Advancing Age Reduces Response to GSK’s Inactivated Hepatitis A Vaccine in Healthy Adults

O. Van Der Meeren, P. Crasta, M. De Ridder

1 GSK Vaccines, Wavre, Belgium, 2 GSK Pharmaceutical Ltd., Mumbai, India, 3 Université Libre de Bruxelles, Brussels, Belgium
**PO03.17**

A Prospective Clinical Trial of Hepatitis B Vaccine in Adults with Type II Diabetes Mellitus

O. Van Der Meeren¹, M. Dionne², J. Peterson³, P. Ebeling⁴, R. Beasley⁵, P. Rheault⁶, R. Simpson⁷, M. Nissen⁸,⁹, M. De Ridder¹⁰, P. Crasta¹¹, J. Miller¹², A. Trofa¹²

¹GlaxoSmithKline, Vaccine Discovery and Development, Wavre, Belgium, ²Centre Hospitalier Universitaire, Quebec, Canada, ³J. Lewis Research, Salt Lake City, United States, ⁴School for Clinical Sciences, Faculty of Medicine, Nursing and Health Sciences, Monash University, Department of Medicine, Victoria, Australia, ⁵Medical Research Institute of New Zealand, Wellington, New Zealand, ⁶Medicor Research, Sudbury, Canada, ⁷Eastern Clinical Research Unit, Monash University, and Eastern Health, Box Hill, Department of Medicine, Victoria, Australia, ⁸GSK Vaccines, Singapore, Singapore, ⁹Laboratory, Department of Cellular & Molecular Pathology, School of Medicine, Faculty of Health Sciences, University of Queensland, Queensland, Australia, ¹⁰GSK Vaccines, Wavre, Belgium, ¹¹GSK Pharmaceutical Ltd., Mumbai, India, ¹²GSK Vaccines, Philadelphia, United States

**PO03.18**

Immune Response after 3 Intradermal Rabies Pre-exposure Injections over Time: A Single Centre Experience

P. Soentjens¹, ², P. Geeraerts³, C. Maussen⁴, B. Henrion⁴, A. Van Gompel², E. Bottieau²

¹Military Hospital Queen Astrid, Centre for Infectious Diseases, Brussels, Belgium, ²Institute of Tropical Medicine, Clinical Sciences, Antwerp, Belgium, ³Staff Department of Well Being, Health Division, Belgian Defense, Brussels, Belgium, ⁴Military Hospital Queen Astrid, Brussels, Belgium

**Infectious Diseases (Epidemiology, Diagnosis, Treatment)**

**PO04.01**

Comparison of Different Tests for Chlamydia Trachomatis Screening

M. He, L. Hua, G. Yan

Shanghai International Travel Healthcare Center, Shanghai, China

**PO04.02**

Management of Imported Cutaneous Larva Migrans: A Case Series

L. Kincaid¹, M. Klowak², S. Klowak³, A.K. Boggild³,⁴,⁵

¹University of Toronto, Department of Medicine, Division of Dermatology, Toronto, Canada, ²McMaster University, Hamilton, Canada, ³Tropical Disease Unit, Toronto General Hospital, Toronto, Canada, ⁴Public Health Ontario Laboratories, Toronto, Canada, ⁵University of Toronto, Department of Medicine, Toronto, Canada
Posters, continued

PO04.03
Rapid Differentiation of Filariae in Unstain and Stain-paraffin-embedded Sections by a HRM-PCR Assay
S. Wongkamchai¹, B. Mayoon², N. Kanakul³, S. Foongladda², D. Wanachiwanawin³, H. Nochote¹, S. Loymek⁴
¹Faculty of Medicine Siriraj Hospital, Mahidol University, Department of Parasitology, Bangkok, Thailand, ²Faculty of Medicine Siriraj Hospital, Mahidol University, Department of Microbiology, Bangkok, Thailand, ³Faculty of Medicine Siriraj Hospital, Mahidol University, Department of Pathology, Bangkok, Thailand, ⁴Phikulthong Royal Development Study Center, Filaria Project, Narathiwart, Thailand

PO04.04
Identification of Leptospiral Low Molecular Weight Membrane Proteins for Early Diagnosis of Leptospirosis
U. Kositanont¹, A. Sitthipunya², C. Pakdeecharoen¹, G. Doungchawee², A. Sereemaspun³, V. Thongboonkerd⁴
¹Faculty of Medicine Siriraj Hospital, Mahidol University, Department of Microbiology, Bangkok, Thailand, ²Faculty of Science, Mahidol University, Department of Pathobiology, Bangkok, Thailand, ³Faculty of Medicine, Chulalongkorn University, Department of Anatomy, Bangkok, Thailand, ⁴Faculty of Medicine Siriraj Hospital, Mahidol University, Medical Proteomics Unit Office for Research and Development, Bangkok, Thailand

PO04.05
Measles, Mumps, Rubella, and Varicella: Using Locally Derived Samples to Determine Differences in Seroprevalence by Birth Cohort
G. Rosario Rosario¹, M. Gareca², M. Knouse², H. Kincaid³
¹Lehigh Valley Health Network, Internal Medicine, Allentown, United States, ²Lehigh Valley Health Network, Internal Medicine - Infectious Disease Division, Allentown, United States, ³Lehigh Valley Health Network, Network Office of Research & Innovation, Allentown, United States

PO04.06
Reasons for Outpatient Visits by Foreign Travellers to an Urban Hospital in Tokyo
N. Matsuda, T. Naito, Y. Uehara, T. Hisaoka
Juntendo University, General Medicine, Bunkyo-ku, Japan
**PO04.07**

**Tuberculosis Infection in Travelers: Screening and Serial Testing with an Interferon Gamma Release Assay in 8431 French Travelers**


*CMETE, Paris, France*

**PO04.08**

**Brucellosis in Israeli Travelers**

I. Kliers\(^1\), Y. Glazer\(^2\), E. Anis\(^2\), E. Schwartz\(^1\)

\(^1\)Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Center for Geographic Medicine, Tel Hashomer, Israel, \(^2\)Israeli Ministry of Health, Division of Epidemiology, Jerusalem, Israel

**PO04.09**

**The Efficacy of Three Novel Tetracyclic Iridoids Isolated from Morinda lucida against Leishmania spp.**

M. Amoa-Bosompem\(^1\), M. Suzuki\(^{1,2}\), K.D. Kwofie\(^1\), M.T. Mosore\(^1\), R. Adegle\(^3\), H.N. Tung\(^4\), T. Uto\(^5\), O. Morinaga\(^4\), W.K. Anyan\(^1\), S. Yamaoko\(^2\), K. Koram\(^1\), N. Ohta\(^2\), D. Edoh\(^5\), N. Puplampu\(^1\), G.K. Nuako\(^6\), P. Bates\(^6\), Y. Shoyama\(^4\), I. Ayi\(^1\), D.A. Boakye\(^1\), I. Agyapong\(^1\)

\(^1\)Noguchi Memorial Institute For Medical Research, Parasitology, Accra, Ghana, \(^2\)Tokyo Medical and Dental University, Tokyo, Japan, \(^3\)Centre for Scientific Research into Plant Medicine, Mampong, Ghana, \(^4\)Nagasaki International University, Nagasaki, Japan, \(^5\)Centre for Scientific Research into Plant Medicine, Mampong, Japan, \(^6\)Lancaster University, Lancaster, United Kingdom

**PO04.10**

**Ebola; A Migrating Global Disease**

M. Nkangu Nguilefem\(^1\), O.A. Olatunde\(^{2,3}\), S. Yaya\(^4\)

\(^1\)University of Ottawa, Population Health, Ottawa, Canada, \(^2\)Dalhousie University, Family Medicine, Halifax, Canada, \(^3\)Society for Good Health, Ibadan, Nigeria, \(^4\)University of Ottawa, Ottawa, Canada

**PO04.11**

**A Potential Role of Tetrahymena Ciliates in the Transmission of Legionnaires’ Disease**

H. Abdelhady, R. Garduño

*Dalhousie University, Halifax, Canada*
PO04.12
Imported Systemic Helminthic Infections in a Tertiary Care Centre in the Czech Republic
F. Stejskal¹, M. Trojanek², L. Kolarova³
¹Regional Hospital Liberec, Department of Infectious Diseases, Liberec, Czech Republic, ²Charles University, 2nd Faculty of Medicine, 1st Department of Infectious Diseases, Bulovka Hospital, Prague, Czech Republic, ³1st Faculty of Medicine, Charles University, Institute of Immunology and Microbiology, Prague, Czech Republic

PO04.13
Azithromycin MICs for Salmonella Typhi Isolated in Singapore but Imported from Asia
T. Barkham, U. Govalla, S. Zainala
Department of Laboratory Medicine, Tan Tock Seng Hospital

Long-stay Travellers (Including Expatriates)

PO05.01
Current Medical Support for the Employees Overseas in India as the Company Hospital
K. Miyagi, M. Osabe
Nagasaki Shipyard & Machinery Works Hospital, Mitsubishi Heavy Industries, Ltd., Department of Internal Medicine, Nagasaki, Japan

PO05.02
Travel-associated Infectious Diseases in Long-term Expatriates to Africa: Surveillance Analysis from Sichuan International Travel Healthcare Center in 2014
J. Meng, R. Ni, J. Wang, Y. Shu, L. Jin, L. Tian, G. Gao
Sichuan International Travel Healthcare Center, Chengdu, China

PO05.03
Mexican Expatriates: Monitoring Mental Health during their Stay Abroad
X. Vite-Velazquez, J.B. Díaz-Ramírez, S. Ponce de León R., P.A. Reyes
Preventive Care Traveler's Clinic (CAPV), UNAM, Research Division, Mexico, Mexico
Posters, continued

Malaria

PO06.01
Concurrent Dengue and Malaria: To Alert the Domestic Traveler. A Case Report
Evandro Chagas Institute, Ananindeua, Brazil

PO06.02
Time Series Analysis of Diagnostic Assays in Plasmodium Falciparum Malaria
M. Phuong¹, R. Lau², F. Ralevski², A.K. Boggild²,³,⁴
¹McMaster University, Hamilton, Canada, ²Public Health Ontario Laboratories, Toronto, Canada, ³University of Toronto, Department of Medicine, Toronto, Canada, ⁴Tropical Disease Unit, Toronto General Hospital, Toronto, Canada

PO06.03
Molecular Surveillance for Drug Resistant Plasmodium Falciparum Imported to Ontario
R. Lau¹, R. Kariyawasam¹, S.N. Patel¹,², F. Ralevski¹, A.K. Boggild¹,³,⁴
¹Public Health Ontario Laboratories, Toronto, Canada, ²University of Toronto, Department of Pathobiology and Laboratory Medicine, Toronto, Canada, ³Tropical Disease Unit, Toronto General Hospital, Toronto, Canada, ⁴University of Toronto, Department of Medicine, Toronto, Canada

PO06.04
Variation in Recommendations for Malaria Prophylaxis
P. Teitelbaum, H. Birk, J. Levere
Riverside Travel Medicine Clinic, Ottawa, Canada

PO06.05
Repeated Relapses of Plasmodium Vivax Acquired in Papua New Guinea Due to Impaired Hepatic Primaquine Metabolism
R.J.H. Ingram¹, C. Crenna-Darusallam², S. Soebianto³, R. Noviyanti¹, J.K. Baird³,⁴
¹ADHB, Auckland, New Zealand, ²Eijkman Institute for Molecular Biology, Jakarta, Indonesia, ³Eijkman-Oxford Clinical Research Unit, Jakarta, Indonesia, ⁴Centre for Tropical Medicine, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
PO06.06
Anti-Plasmodial Properties of Some Selected Ghanaian Medicinal Plants: Identification of Novel Active Compounds against Plasmodium Falciparum
J. Agyapong1, M. Suzuki1,2, G.A. Awandare3, M. Ofori4, I. Ayi1, E. Frimpong5, D. Boakye1
1Noguchi Memorial Institute for Medical Research, Parasitology, Accra, Ghana, 2Tokyo Medical and Dental University, Tokyo, Japan, 3University of Ghana, Department of Biochemistry, Cell & Molecular Biology, Accra, Ghana, 4Noguchi Memorial Institute for Medical Research, Immunology, Accra, Ghana, 5Kwamen Nkrumah University of Science and Technology, Molecular Microbiology, Kumasi, Ghana

PO06.07
Development and Application of Liquid Bead Array Method for the Detection of Plasmodium
J. Yan, L. Shi, Y. Li
Hebei International Traval Health-Care Center, Shijiazhuang, China

PO06.08
Overseas Imported Malaria Brings Challenge to China Malaria Elimination: A Malaria Cases Retrospective Analysis in Hubei Province, 2009-2014
R. Gong, X. Guo, X. Zhuang
Hubei International Travel Healthcare Center, Wuhan, China

PO06.09
Efficacy and Safety of Intravenous Artesunate in Adult Travelers Presenting with Imported Severe Plasmodium Falciparum Malaria
C. Rapp1, V. Lamand2, P. Le Garlantezec2, C. Ficko1, O. Aoun1, C. Flateau1, C. Dubost3, J. Giraud2, D. Andriamanantena1
1HIA Bégin, Infectious Diseases Department, Saint-Mandé, France, 2HIA Bégin, Pharmacy, Saint-Mandé, France, 3HIA Bégin, Intensive Care Medicine, Saint-Mandé, France

PO06.10
Efficacy and Safety of Dihydroartemisinin-piperaquine in Real Life Conditions in Adults Presenting with Imported Malaria
C. Rapp1, P. Le Garlantezec2, C. Ficko1, C. Flateau1, D. Andriamanantena1, M. Muller2, V. Lamand3, O. Aoun1, J. Giraud2
1HIA Bégin, Infectious Diseases Department, Saint-Mandé, France, 2HIA Bégin, Pharmacy, Saint-Mandé, France
**Posters, continued**

**PO06.11**
**Imported Malaria in a Changing Greece: A 20-year Survey**
C.M. Vassalos¹, E. Vassalou²
¹National School of Public Health, Travel Unit, Department of Parasitology, Athens, Greece,
²National School of Public Health, Malaria Reference Laboratory, Travel Unit, Athens, Greece

**Migrants and Refugees**

**PO07.01**
**Overcoming Language Barriers: Training and Integrating Community Interpreters in a Refugee Health Clinic**
R. Rocque¹, S. Gagnon¹, C. Brisset², Y. Leanza¹
¹University Laval, Quebec, Canada, ²Université de Bordeaux, Bordeaux, France

**PO07.02**
**A Missed Opportunity: Integrating VFR Travel Medicine into Primary Care at FQHCs**
N. Piper Jenks, J. Koren, L. Gleason
HudsonRiver Health Care, Inc, Peekskill, United States

**PO07.03**
**The Trends of Tuberculosis Prevalence among Foreign Workers in Taiwan, 2004-2013**
Y.-H. Pan¹, C.-W. Lu², L.-J. Wu³, Y.-C. Wu³, S.-Y. Cheng², K.-C. Huang²
¹National Taiwan University Hospital Yun-Lin Branch, Yunlin, Taiwan, Department of Community and Family Medicine, Douliou, Taiwan, Republic of China,
²National Taiwan University Hospital, Department of Family Medicine, Taipei, Taiwan, Republic of China,
³Taiwan Center for Disease Control, Ministry of Health and Welfare, Taipei, Taiwan, Republic of China
PO07.04
Comparison of Rates of Uptake of Preventive Measures between Canadian VFR Travellers and Non VFR Travellers Going to High-risk Destinations
Y.G. Bui1,2,3, S.M. Kuhn4,5, T. Rahman6,7, M. Sow3, A. McCarthy8,9, J. Geduld6, F. Milord2,3
1Institut National de Santé Publique du Québec, Longueuil, Canada, 2CSSS Champlain-Charles-LeMoyne, Department of Public Health, Longueuil, Canada, 3Université de Sherbrooke, Department of Community Health, Longueuil, Canada, 4University of Calgary, Departments of Pediatrics and Medicine, Calgary, Canada, 5Alberta Children’s Hospital, Section of Pediatrics Infectious Diseases, Calgary, Canada, 6Public Health Agency of Canada, Travel and Migration Health Division, Ottawa, Canada, 7University of Toronto, Toronto, Canada, 8University of Ottawa, Department of Medicine, Ottawa, Canada, 9The Ottawa Hospital, Tropical Medicine and International Health Clinic, Division of Infectious Disease, Ottawa, Canada

PO08.01
Profile of Travellers with Pre-existing Medical Conditions Attending a Specialised Travel Medicine Clinic
C.J.H. Teo1, G.T. Flaherty1,2,3
1School of Medicine, National University of Ireland, Galway, Ireland, 2International Medical University, Kuala Lumpur, Malaysia, 3Travel Medicine Society of Ireland, Dublin, Ireland

PO08.02
Field Efficacy of Herbal Repellent against Biting Midges in Thailand
A. Tawatsin1, U. Thavara1, J. Chompoosri1, P. Bhakdeenuan1, P. Kunhachan1, S. Sangkitporn1, P. Siriyasatien2,3
1National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand, 2Chulalongkorn University, Faculty of Medicine, Department of Parasiology, Bangkok, Thailand, 3Excellence Center for Emerging Infectious Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand

PO08.03
Travelers’ Thrombosis Risk Factors and Perception Survey at Mexico City International Airport
Preventive Care Traveler’s Clinic (CAPV), UNAM, Research Division, Mexico, Mexico
Pre-travel Health Advice Guidelines for Humanitarian Workers: A Systematic Review
M. Costa, M. Oberholzer-Riss, C. Hatz, R. Steffen, P. Schlagenhauf
University of Zurich Centre for Travel Medicine, WHO Collaborating Centre for Travelers’ Health, Epidemiology, Biostatistics and Prevention Institute, Zürich, Switzerland

Giardia Intestinalis Diarrhea-related Reactive Arthritis in a French Soldier Repatriated from Mali
O. Aoun, L. Biale, F. Banal, I. Imbert, C. RAPP, D. Lechevalier
HIA Bégin, Infectious Diseases, Saint-Mande Cedex, France

Diminishing Returns: Post-deployment Screening for Latent Tuberculosis Infection in the Canadian Armed Forces
M. Tepper, F. Crane, S. Schofield, M. Patel, P. Eagan
Royal Canadian Medical Service, Directorate of Force Health Protection, Ottawa, Canada

Knowledge, Attitude and Practice of Travelers about Travel Risks Related to Food
Z. Obradovic
Public Health Institute/ Faculty for Health Studies University of Sarajevo, Epidemiology, Sarajevo, Bosnia and Herzegovina

Telemedicine for Health Problems while Abroad: Are Travelers Interested and Willing to Pay Prior to Departure?
L. Rochat, V. D'Acremont, B. Genton
University Hospital, Ambulatory Care and Community Medicine, Travel Clinic, Lausanne, Switzerland, Swiss Tropical and Public Health Institute, Basel, Switzerland
PO10.03
US Entry Screening for Persons Arriving from West Africa to Control the Spread of Ebola, October 11 - November 30, 2014
U.S. Centers for Disease Control and Prevention, Atlanta, United States

PO10.04
Medical Evacuations in the Oil and Gas Industry - A Retrospective Review with Implications for Future Evacuation and Preventative Strategies
H. Berg¹, H. Williams², S. Toner¹, S. Klein¹, R. Stilz¹, N. Nerwich³, S. Marshall¹, H. Mohamed¹, R. Copeland³
¹Shell Health, Shell International B.V., The Hague, Netherlands, ²Aberdeen Centre for Trauma Research, Institute for Health and Wellbeing Research, Robert Gordon University, Aberdeen, United Kingdom, ³International SOS (Intl SOS), London, United Kingdom

PO10.05
Student Travel Abroad: ISTM Clinicians Identify Priorities for Research, Education and Action
G. Rosselot
Travel Well of Westchester, Briarcliff Manor, United States

PO10.06
Digital Advertising to Travelers - Leveraging Current Events for Optimal Reach
M. O’Sullivan², L. Preis², S. Waldron², K. Holton¹
¹Centers for Disease Control and Prevention, Division of Global Migration and Quarantine, Atlanta, United States, ²Multiple, Inc., Atlanta, United States

PO10.07
Medical Student Electives: Quantifying the Travel Health Risks for Different Destinations - A Nine Year Study
L.I. Ford¹, M.B. Beadsworth¹, M.J. Platt¹, N.J. Beeching¹
¹Liverpool School of Tropical Medicine, Clinical Research Group, Liverpool, United Kingdom, ²Royal Liverpool University Hospital, Infectious Diseases, Liverpool, United Kingdom, ³School of Medicine, University of Liverpool, Liverpool, United Kingdom
Pre-travel Advice and Approaches (Including Risk Assessment/Communication)

PO11.01
The Use of Hand Sanitizers among Dutch Travelers Visiting (Sub)Tropical Destinations
J.A. Vlot, L.G. Visser
Leiden University Medical Center (LUMC), Infectious Diseases, Leiden, Netherlands

PO11.02
Evaluation of Pre-travel Preparation of Travelers Visiting Sub-Saharan Africa
A. Pavli1, S. Hadzianastasiou1, P. Smeti1, A. Spilioti1, Z. Ouzounidou1, P. Katerelos1, H.C. Maltezou2
1Hellenic Centre for Disease Control and Prevention, Travel Medicine Office, Athens, Greece,
2Regional Department of Public Health and Social Welfare, South Aegean, Ermoupolis, Greece

PO11.03
The Role of Digital Health Tools in Optimizing a Patient’s Travel Health Experience and Care: From the Pre-Travel Assessment to Remote Health and Medication Adherence Monitoring
A. Sihota1,2
1University of British Columbia Vancouver (UBC) Faculty of Pharmaceutical Sciences Alumni, Vancouver, Canada, 2Sina Pharmacy and Travel Health Center, Vancouver, Canada

PO11.04
Pre-travel Counselling at a Public Travel Medicine Clinic in Brazil
T.S.S. Chaves1,2, J.R. Alves2, M.H. Lopes3
1Evandro Chagas Institute, Ananindeua, Brazil, 2Emilio Ribas Infectious Diseases Institute, Travel Medicine, São Paulo, Brazil, 3University of São Paulo School of Medicine (FMUSP), Department of Clinical Infectious and Parasitic Diseases, Sao Paulo, Brazil

PO11.05
Routine Vaccination Perceptions and Behaviors during the Pre-travel Consultation
S.K. Erskine1, C.V. Lee1, H. Scott2, B. Wilburn3, L. Dye3, N.K. Holton1
1Centers for Disease Control and Prevention, Division of Global Migration and Quarantine, Atlanta, United States, 2Oak Ridge Associated Universities/Oak Ridge Institute for Science and Education, Health and Safety Communication Group, Oak Ridge, United States, 3Oak Ridge Associated Universities/Oak Ridge Institute for Science and Education, Health, Energy, and Environment, Oak Ridge, United States
**PO11.06**

**User Testing a Mobile Application for Travel Health: The TravWell Experience**

R. Henry\(^1\), M. O'Sullivan\(^1\), K. Bursey\(^2\), M. Hermanson\(^3\), D. Krause\(^1\), L. Lange\(^2\), J. Power\(^4\), K. Spruit-McGoff\(^3\), P. Williams\(^4\), K. Holton\(^1\)

\(^1\)Centers for Disease Control and Prevention, Atlanta, United States, \(^2\)Oak Ridge Associated Universities, Oak Ridge, United States, \(^3\)Oak Ridge Associated Universities, Oaky Ridge, United States, \(^4\)Duet Health, Columbus, United States

---

**PO11.07**

**Refusal of Recommended Vaccines among U.S. International Travelers in Global TravEpiNet**

S. Lammert\(^1\), E. Jentes\(^2\), S. Erskine\(^3\), S. Hagmann\(^3\), S.R. Rao\(^4,5\), E. Ryan\(^1,6\), R. LaRocque\(^1,6\), the Global TravEpiNet Consortium

\(^1\)Massachusetts General Hospital, Travelers' Advice and Immunization Center, Boston, United States, \(^2\)Centers for Disease Control and Prevention, Division of Global Migration and Quarantine, Atlanta, United States, \(^3\)Bronx-Lebanon Hospital Center, Division of Pediatric Infectious Diseases, Bronx, United States, \(^4\)University of Massachusetts Medical School, Department of Quantitative Health Sciences, Worcester, United States, \(^5\)Bedford VA Medical Center, Center for Health Quality, Outcomes, and Economics Research, Bedford, United States, \(^6\)Harvard Medical School, Boston, United States

---

**PO11.08**

**Developing Travel Health Recommendations in Canada: Adapting Evidence Based Methods**

C. Greenaway\(^1\), S. Schofield\(^2\), J. Geduld\(^3\), Committee to Advise on Tropical Medicine and Travel (CATMAT)

\(^1\)McGill University, Department of Microbiology, Montreal, Canada, \(^2\)Department of National Defence, Ottawa, Canada, \(^3\)Public Health Agency of Canada, Ottawa, Canada
PO11.09
Canada's Recommendations for Travel Health: The Role of the Committee to Advise on Tropical Medicine and Travel (CATMAT)
1Ottawa Hospital General Campus, Division of Infectious Disease, Ottawa, Canada, 2University Health Network and the University of Toronto, Department of Medicine, Toronto, Canada, 3Children’s Hospital of Eastern Ontario, Division of Infectious Diseases, Ottawa, Canada, 4Institut National de Santé Publique du Québec, Longueuil, Canada, 5University of Manitoba, Winnipeg, Canada, 6McGill University, Department of Microbiology, Montreal, Canada, 7McGill University Health Centre, Division of Infectious Disease, Montreal, Canada, 8Riverside Travel Medicine Clinic, Ottawa, Canada, 9Alberta Health Services, Calgary, Canada, 10Department of National Defence, Ottawa, Canada, 11Health Canada, Ottawa, Canada, 12Centers for Disease Control and Prevention, Atlanta, United States, 13McMaster University, Division of Pediatric Infectious Disease, Hamilton, Canada

PO11.10
Risk Communication to Travelers During the 2014 Ebola Outbreak
A. Lee, H. Bair-Brake, G. Benenson, S. Erskine, K. Holton, R. Myers, M. O'Sullivan, N. Ovens, A. Shaw, K. Spruit-McGoff, C. Uribe, E. Willacy, the Global Migration Task Force Communications Team
Centers for Disease Control and Prevention, Atlanta, United States

PO11.11
Improving Usability and User Experience for the CDC Travelers’ Health Website to Facilitate the Accessibility of Pre-travel Advice
K. Holton1, A.W. Lee1, R.E. Henry1, M.C. O’Sullivan1, K. Spruit-McGoff1, S. Schuffenhauer2, C. Oliver2
1Centers for Disease Control and Prevention, Travelers’ Health Branch, Atlanta, United States, 2Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases, Atlanta, United States
Pre-travel Advice, Attitude and Hepatitis A and B Vaccination Rates among Travelers in Seven Countries
D. Tessier1,2, A. Heywood3, M. Moodley4, H. Nothdurft5, L. Rombo6, C. Marano7, L. De Moerlooze7
1Groupe Santé Voyage, Quebec, Canada, 2University of Montréal, Montreal, Canada, 3School of Public Health and Community Medicine, UNSW, Sydney, Australia, 4IPSOS Healthcare, London, United Kingdom, 5Hans Nothdurft Consulting, Munich, Germany, 6FoU Centrum, Eskilstuna, Sweden, 7GSK Vaccines, Wavre, Belgium

Level of Concern about Safety and Security Traveling Abroad in Queensland, Australia: A Preliminary Analysis
P.A. Leggat1,2,3, R.C. Franklin1,2, J.C. King1,2
1James Cook University, Anton Breinl Centre, Townsville, Australia, 2James Cook University, World Safety Organization Collaborating Centre, Townsville, Australia, 3University of the Witwatersrand, School of Public Health, Faculty of Health Sciences, Johannesburg, South Africa

Improving Access to a University Travel Clinic for Students Studying Abroad
L.K. Johnson, J. Kind, C. Jones, K. Seymour-Howell
University of Wisconsin, Health Services, Madison, United States

“Touch Malaria”: The First Multi-touch Book about Vector-borne Diseases
E. Artosi1, A. Canciani2, G. Mainardi2, S. Senatore2, A.F. Marino3, L. Trotta1, M. Faccini2, A. Rossanese4
1ASL Milano, Graduation Course for Physician Assistants, Milano, Italy, 2ASL Milano, Dept. of Prevention, Milano, Italy, 3University of Milano, School of Specialization in Hygiene and Preventive Medicine, Milano, Italy, 4’Sacro Cuore-Don Calabria’ Hospital, Centre for Tropical Diseases, Negrar, Italy
Professional Education and Training

PO12.01
Travel Health and Registered Nurse (RN) Prescribers in Manitoba
J. Daoudi¹, C. Wickens², J. Shackel³, P. Plourde¹, R. Lock³, C. Rogoza³, D. Elias⁴
¹Winnipeg Regional Health Authority, Winnipeg, Canada, ²Northern Regional Health Authority, Flin Flon, Canada, ³Red River College, Winnipeg, Canada, ⁴College of Registered Nurses of Manitoba, Winnipeg, Canada

PO12.02
Travel Health Advisory Group: A Joint Travel Industry and Travel Health Initiative Promoting Healthy Travel in Australia
P.A. Leggat¹,², B. Hudson¹,³, N. Zwar⁴, Travel Health Advisory Group, Australia
¹James Cook University, Anton Breinl Centre, Townsville, Australia, ²University of the Witwatersrand, School of Public Health, Faculty of Health Sciences, Johannesburg, South Africa, ³Royal North Shore Hospital, Department of Microbiology and Infectious Diseases, Sydney, Australia, ⁴University of New South Wales, School of Public Health and Community Medicine, Sydney, Australia

PO12.03
The Faculty of Travel Medicine - Generating Change and Setting Standards
M.E. Jones¹, E. Walker², A.D. Green³
¹Royal College of Physicians and Surgeons of Glasgow, Faculty of Travel Medicine, Glasgow, United Kingdom, ²University of Glasgow, Dept of General Practice, Glasgow, United Kingdom, ³Ministry of Defence, Infection Prevention and Control, Birmingham, United Kingdom

PO12.04
Multidisciplinary Travel Health Practice in Alberta
A. Acharya, C. Ellis, B. Burrows
Bowmont Travel Clinic, Calgary, Canada

Returning Travellers

PO13.01
Assessment of PEP and PrEP Given to Danish Travellers to Rabies Endemic Countries, 2000-2012
A.H. Christiansen, L.K. Knudsen
Statens Serum Institute, Department of Infectious Epidemiology, Copenhagen, Denmark
PO13.02
Retrospective Analysis of Post-travel Consultation in the Travel Clinic of Kurume University Hospital, Japan
K. Yaita, Y. Sakai, J. Iwahashi, K. Masunaga, N. Hamada, H. Watanabe
Kurume University Hospital, Department of Infection Control and Prevention, Fukuoka, Japan

PO13.03
Implementation and Evaluation of a Rapid Assessment Clinic for Febrile Returned Travelers in Ambulatory Tropical Medicine
F. Jazuli1, M. Klowak2, A.K. Boggild3,4,5
1University of Toronto, Toronto, Canada, 2McMaster University, Hamilton, Canada, 3Tropical Disease Unit, Toronto General Hospital, Toronto, Canada, 4University of Toronto, Department of Medicine, Toronto, Canada, 5Public Health Ontario Laboratories, Toronto, Canada

PO13.04
Screening the (Asymptomatic) Returning Traveler after a Stay in Sub-Saharan Africa: Experience in a Military Cohort
P. Vanbrabant1, A. Wauters1, P. Tavernier1, M. Ruyffelaert1, E. Dooms1, C. Maussen1, M. Van Esbroeck1, P. Soentjens1
1Military Hospital Queen Astrid, Polyclinic Department, Neder-over-Heembeek, Belgium, 2Institute of Tropical Medicine, Antwerp, Belgium

PO13.05
Health Problems among Thai Tourists Returning from India
J. Olanwijitwong1, K. Poovorawan2, S. Lawpoolsri2, P. Chanthavanich1, P. Wichianprasat2, W. Piyaphanee2
1Faculty of Tropical Medicine, Mahidol University, Hospital for Tropical Diseases, Bangkok, Thailand, 2Faculty of Tropical Medicine, Mahidol University, Department of Clinical Tropical Medicine, Bangkok, Thailand

PO13.06
Respiratory Pathogens Surveillance in Returning South African Pilgrims after the 2013 Hajj: Johannesburg OR Tambo International Airport
S. Parker1, L. Blumberg2, A. Takalani3
1South African Society of Travel Medicine (SASTM), Johannesburg, South Africa, 2National Institute for Communicable Diseases (NICD), Johannesburg, South Africa, 3University of Witwatersrand, Johannesburg, South Africa
PO13.07
Workplace Response to the Ebola Virus Disease (EVD) Outbreak in Nigeria and Returning Travelers - The ExxonMobil Experience
A.E. Ben-Edet1, B. Aliyu1, M. Diara2, N. Susan1, E. Abbah1, I. Owodiong-Idemeko3, N. Cookey-Gam4
1ExxonMobil, Medicine and Occupational Health Department, Lagos, Nigeria, 2ExxonMobil, Medicine and Occupational Health Department, Houston, United States, 3ExxonMobil, Human Resources, Lagos, Nigeria, 4ExxonMobil, Public and Government Affairs, Lagos, Nigeria

PO13.08
Tick-borne Encephalitis (TBE) in Israeli Travelers: Case Reports and its Prevention
Y. Paran, E. Meltzer, M. Weinberge, A. Wasserman, E. Schwartz
Tel Aviv University, Tel Aviv, Israel

PO13.09
Analysis of Travel Related Behaviors of Dengue Infected Returning Missionaries from Haiti
D.R. Lattanzi, M. Quimper, N. Falls
University of Pittsburgh, School of Medicine, Pittsburgh, United States

PO13.10
Colonization of Returning Travellers with Extended-spectrum Beta-lactamase Producing Escherichia Coli: Prevalence and Risk Factors
C. Flateau1, S. Duron2, R. Haus-Cheymol3, A. Bousquet3, C. Ficko1, D. Andriamanantena1, C. Verret2, A. Merens3, C. Rapp1
1Hôpital Bégin, Service des Maladies Infectieuses, Saint-Mandé, France, 2Centre d'Épidémiologie et de Santé Publique des Armées (CESPA, Marseille, France, 3Laboratoire de Biologie Médicale, Hôpital d'Instruction des Armées Bégin, Saint-Mandé, France

PO13.11
Case-report: Vomiting a « Worm » Long after a Trip to Tunisia
C. Weibel Galluzzo1, F. Chappuis1, A. Mauris2, J.-D. Graf3
1HUG Hôpitaux Universitaires de Genève, Service de Médecine Tropicale et Humanitaire, Geneva, Switzerland, 2HUG Hôpitaux Universitaires de Genève, Laboratoire de Parasitologie, Geneva, Switzerland, 3HUG Hôpitaux Universitaires de Genève, Laboratoire des Liquides Biologiques, Geneva, Switzerland

PO13.12
Multiple Painful Pruritic Papules on the Skin after a ‘Missionary Journey’ to Lagos, Nigeria
G.T. Igodo
Ripples House, Health Centre, Coventry, United Kingdom
Management of Two Humanitarians Presenting with Ebola Virus Disease Following their Medevac to a French Isolation Facility

C. Rapp¹, C. Ficko¹, C. Flateau¹, D. Andriamanantena¹, A. Merens², S. Baize³, C. Dubost⁴, E. Valade⁵, S. Merat⁴

¹HIA Bégin, Infectious Diseases Department, Saint-Mandé, France, ²HIA Bégin, Biology, Saint-Mandé, France, ³Inserm, FHV Reference Center, Lyon, France, ⁴HIA Bégin, Intensive Care Medicine, Saint-Mandé, France, ⁵IRBA, Bacteriology, Bretigny, France

**Special Needs Travellers (Pregnancy, Pediatrics, Elderly, Immunosuppressed)**

Enquiries to the National Travel Advice Helpline by Healthcare Professionals Regarding Travellers with Immunocompromise

J. Allen¹, D. Patel²

¹Hospital for Tropical Diseases, London, United Kingdom, ²National Travel Health Network and Centre, London, United Kingdom

Chinese Students Abroad: An important Category of Travelers

M. He, L. Hua, G. Yan, J. Lu

Shanghai International Travel Healthcare Center, Shanghai, China

Travel Characteristics and Pre-Travel Health Care among Pregnant or Breastfeeding Women Preparing for International Travel: Analysis from the U.S. Global TravEpiNet Consortium


¹Bronx-Lebanon Hospital Center, Division of Pediatric Infectious Diseases, Bronx, United States, ²Albert Einstein College of Medicine, Department of Pediatrics, Bronx, United States, ³University of Massachusetts Medical School, Department of Quantitative Health Science, Worcester, United States, ⁴Bedford VA Medical Center, Center for Health Quality, Bedford, United States, ⁵Massachusetts General Hospital, Division of Infectious Diseases, Boston, United States, ⁶Harvard Medical School, Department of Medicine, Boston, United States, ⁷Centers for Disease Control and Prevention, Division of Global Migration and Quarantine, Atlanta, United States
Posters, continued

**PO14.04**

Traveling with HIV - Centro Hospitalar do Porto Experience in Is Travel Medicine Center Unit - July 2013 to December 2014
L.A.C. Silva\textsuperscript{1}, S. Xará\textsuperscript{2}, R. Sarmento e Castro\textsuperscript{1}
\textsuperscript{1}CHP, Infectious Diseases, Porto, Portugal, \textsuperscript{2}CHP, Porto, Portugal

**Trauma, Security, Disasters and Conflicts**

**PO15.01**

Health Screening for an Escalating Ebola Response
L. Rea, P. Jones, E. Pine, T. Lankester, S. Clift
InterHealth Worldwide, London, United Kingdom

**Travel Medicine Practice**

**PO16.01**

Incorporating Comprehensive Travel Health Services in Primary Care
A. Dizdarevic\textsuperscript{1,2}, K. Dixon\textsuperscript{3}
\textsuperscript{1}Copeman Healthcare Centre, Vancouver, Canada, \textsuperscript{2}University of British Columbia, Vancouver, Canada, \textsuperscript{3}Copeman Healthcare Centre, Calgary, Canada

**PO16.02**

International Travelers from New Jersey: Piloting a Travel Medicine Module in the 2011 Behavioral Risk Factor Surveillance System Survey
R.J. Stoney\textsuperscript{1}, P. Kozarsky\textsuperscript{1}, R. Bostick\textsuperscript{2}, M.J. Sotir\textsuperscript{1}
\textsuperscript{1}Centers for Disease Control and Prevention, Division of Global Migration and Quarantine, Atlanta, United States, \textsuperscript{2}Emory University, Rollins School of Public Health, Department of Epidemiology, Atlanta, United States

**PO16.03**

Travellers’ Profile and Travel Clinic Vaccine Practices: A 10-year Prospective Study in Switzerland
R. Boubaker\textsuperscript{1}, P. Meige\textsuperscript{1}, C. Mialet\textsuperscript{1}, C. Ngarambe Buffat\textsuperscript{1}, M. Uwanyiligira\textsuperscript{1}, F. Widmer\textsuperscript{1}, J. Rochat\textsuperscript{1}, A. Herard Fossati\textsuperscript{1}, M. Souvannaraj-Blanchant\textsuperscript{1}, S. Payot\textsuperscript{1}, S. de Vallière\textsuperscript{1,2}, B. Genton\textsuperscript{1,2,3}, V. D’Acremont\textsuperscript{1,3}
\textsuperscript{1}Travel Clinic, Department of Ambulatory Care and Community Medicine, University Hospital, Lausanne, Switzerland, \textsuperscript{2}Infectious Disease Service, University Hospital, Lausanne, Switzerland, \textsuperscript{3}Swiss Tropical and Public Health Institute, Basel, Switzerland
PO16.04
Risk Assessment for an Early Hospital Readmission
F. Sestier¹, A. Naslafkhi²
¹University of Montreal, Programme de Médecine d’Assurance, Montreal, Canada, ²University of Montreal, Program of Insurance Medicine, Montreal, Canada

PO16.05
Managing Travellers Seeking Treatment Abroad: Experiences from a Host Country
S. Chatterjee
Pulse Diagnostics Pvt Ltd, Kolkata, India

PO16.06
The Development of the Travel Medicine in Hungary - Retrospection 10-years after the Country has Joined the EU
P.P. Felkai
SOS Hungary Medical Service, Management, Budapest, Hungary

PO16.07
A Portrait of Travel Health Services in Canada in the Midst of a Changing Regulatory Environment
Y.-G. Bui¹²³, S.M. Kuhn⁴⁵, M. Sow⁶, A. McCarthy⁶⁷, J. Geduld⁸, F. Milord²³
¹Institut national de Santé Publique du Québec, Longueuil, Canada, ²CSSS Champlain-Charles-LeMoyne, Department of Public Health, Longueuil, Canada, ³Université de Sherbrooke, Department of Community Health, Longueuil, Canada, ⁴University of Calgary, Departments of Pediatrics and Medicine, Calgary, Canada, ⁵Alberta Children’s Hospital, Section of Pediatrics Infectious Diseases, Calgary, Canada, ⁶University of Ottawa, Department of Medicine, Ottawa, Canada, ⁷The Ottawa Hospital, Tropical Medicine and International Health Clinic, Division of Infectious Disease, Ottawa, Canada, ⁸Public Health Agency of Canada, Travel and Migration Health Division, Ottawa, Canada

PO16.08
Improving Oral Typhoid Vaccine Adherence in a Travel Clinic
R. Martin¹, K.A. Avery¹, F.A. Manning¹, L.H. Chen¹²
¹Mount Auburn Hospital, Travel Medicine Center, Cambridge, United States, ²Harvard Medical School, Boston, United States
Vector-borne Infections (Excluding Malaria)

**PO17.01**

Role of Leishmania RNA Virus-1 in the Pathogenesis of Tegumentary Leishmaniasis

B.M. Valencia¹, R. Lau², A. Llanos-Cuentas¹, A.K. Boggild²,³,⁴

¹Universidad Peruana Cayetano Heredia, Instituto de Medicina Tropical ‘Alexander von Humboldt’, Lima, Peru, ²Public Health Ontario Laboratories, Toronto, Canada, ³Tropical Disease Unit, Toronto General Hospital, Toronto, Canada, ⁴University of Toronto, Department of Medicine, Toronto, Canada

**PO17.02**

Dengue During Travel in Singapore: Severe Dengue is Associated with Longer Residence in Endemic Regions

P.L. Lim¹,², P. Han³, D. Esposito³, D.O. Freedman⁴

¹Institute of Infectious Diseases & Epidemiology, Tan Tock Seng Hospital, Infectious Diseases, Singapore, Singapore, ²Lee Kong Chian School of Medicine, Singapore, Singapore, ³Centers for Disease Control and Prevention, Atlanta, United States, ⁴University of Alabama at Birmingham, Infectious Diseases, Birmingham, United States

**PO17.03**

Double Dengue Serotypes in Asymptomatic Populations Living in an Area of Thailand Endemic for Dengue Hemorrhagic Fever

V. Kittichai¹, M. Sriprapun², A. Tawatsin³, U. Thavara³, P. Siriyasatien¹,⁴

¹Faculty of Medicine, Chulalongkorn University, Parasitology, Bangkok, Thailand, ²Faculty of Medical Technology, Huachiew Chalermprakiet University, Clinical Microbiology, Bangkok, Thailand, ³National Institute of Health, Ministry of Public Health, Medical Sciences, Nonthaburi, Thailand, ⁴King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Excellence Center for Emerging Infectious Disease, Bangkok, Thailand

**PO17.04**

Molecular Evidence of Rickettsia spp. in Human and Dogs Blood in Bangkok

S. Foongladda¹, N. Mongkol¹, Y. Suputtamongkol²

¹Mahidol University, Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand, ²Mahidol University, Division of Infectious Diseases, Department of Medicine, Faculty of Medicine, Siriraj Hospital, Bangkok, Thailand
Interagency and Commercial Collaboration Utilized during an Investigation of Chikungunya and Dengue among Returning Travelers to the United States


¹Centers for Disease Control and Prevention, Division of Global Migration and Quarantine/Travelers’ Health Branch, Atlanta, United States, ²Centers for Disease Control and Prevention, Atlanta, United States, ³Centers for Disease Control and Prevention, Miami, United States, ⁴AMIGOS de las Americas, Houston, United States, ⁵Centers for Disease Control and Prevention, San Juan, Puerto Rico, ⁶American Airlines, Miami, United States, ⁷Centers for Disease Control and Prevention, Ft. Collins, United States

Myiasis in Travelers

T. Lachish¹, E. Marhoom², K. Mumcuoglu¹, E. Schwartz⁴

¹Shaare-Zedek Medical Center, Infectious Diseases, Jerusalem, Israel, ²The Chaim Sheba Medical Center, Tel Hashomer, Israel, ³The Hebrew University, Department of Microbiology and Molecular Genetics, The Kuvin Center for the Study of Infectious and Tropical Diseases, Jerusalem, Israel, ⁴The Chaim Sheba Medical Center, The Center for Geographic Medicine, Tel Hashomer, Israel

Importance of Working with the Travel and Tourism Industries for Dengue Prevention and Control in Bali, Indonesia - A World-famous Tourist Destination

M.J. Yoshikawa³, E.M. Siska², R. Kusriastuti³,⁴, C. Liew⁵

³Kyoto University, Inter-Graduate School Unit for Sustainable Development and Survivable Societies, Kyoto, Japan, ²Kyoto University, Disaster Prevention and Research Institute, Graduate School of Engineering, Kyoto, Japan, ⁴United Nations Development Programme, Jakarta, Indonesia, ⁵Indonesian Parasitic Diseases Association, Jakarta, Indonesia, ⁶Environmental Health Institute, National Environment Agency, Singapore, Singapore

Establishment of a Multiplex Liquid Bead Array for Detection and Genotyping of Dengue Virus

L. Shi, J. Yan, Y. Li

Hebei International Traval Health-Care Center, Shijiazhuang, China

Chikungunya Virus in the Americas: Impact on Tourism

C. Bitter, J. Lin

University of Illinois - Chicago, Emergency Medicine, Chicago, United States
PO17.10
Molecular Survey of Head Louse Pediculus Humanus Capitis in Thailand and its Potential Role for Transmitting Acinetobacter spp.
U. Thavara¹, S. Sunantaraporn², V. Sanprasert³, T. Pongsakul⁴, A. Phumee³, R. Boonserm³, A. Tawatsin¹, P. Siriyasatien³,⁵
¹National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand, ²Chulalongkorn University, Medical Science Program, Faculty of Medicine, Bangkok, Thailand, ³Chulalongkorn University, Department of Parasitology, Faculty of Medicine, Bangkok, Thailand, ⁴Prince of Songkla University, Faculty of Medical Technology, Songkhla, Thailand, ⁵Excellence Center for Emerging Infectious Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand

PO17.11
ZIKA Virus (ZIKV) Infection in an American Recreational Traveler
D. Summers¹,²,³, M.-L. Scully⁴, R.W. Acosta¹, A.M. Acosta¹,⁵,⁶
¹Traveler’s Medical Service of New York, New York, United States, ²Columbia University, School of Nursing, DNP Program, New York, United States, ³Jonas Scholars Program, Washington DC, United States, ⁴Sansum Clinic, Santa Barbara, United States, ⁵Weill Cornell Medical College, New York, United States, ⁶The New York-Presbyterian Hospital, New York, United States

PO17.12
Seasonal Active Surveillance of Dengue and Chikungunya Viruses-infected Aedes Mosquitoes in Dengue-endemic Provinces, Thailand
J. Chompoosri¹, U. Thavara¹, A. Tawatsin¹, C. Khumsawads¹, P. Bhakdeenuan¹, P. Kunhachan¹, S. Sangkitporn¹, A. Phumee², P. Siriyasatien³,⁵
¹National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand, ²Chulalongkorn University, Faculty of Medicine, Department of Parasitology, Bangkok, Thailand, ³Excellence Center for Emerging Infectious Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand

PO17.13
Development of Lethal Ovitrap with Natural Attractants to Control DHF Vectors
U. Thavara¹, A. Tawatsin¹, J. Chompoosri¹, P. Bhakdeenuan¹, P. Kunhachan¹, S. Sangkitporn¹, P. Siriyasatien²,³
¹National Institute of Health, Department of Medical Sciences, Ministry of Public Health, Nonthaburi, Thailand, ²Chulalongkorn University, Faculty of Medicine, Department of Parasitology, Bangkok, Thailand, ³Excellence Center for Emerging Infectious Diseases, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand
## Sponsored Satellite Programs

Note: All satellite programs will be held in Room 200AB.

### Monday, 25 May 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sponsored by Takeda</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sponsored by Novartis Vaccines, Now a GSK Company</td>
<td></td>
</tr>
</tbody>
</table>

### Tuesday, 26 May 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Sponsored by PaxVax</td>
<td></td>
</tr>
</tbody>
</table>

### Wednesday, 27 May 2015

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.00–14.30</td>
<td>60 Years Legacy in Vaccine Development: Lessons Learned &amp; Outstanding Questions</td>
<td>Olivier Van Der Meeren, William Hausdorff, Marc De Ridder, Alberta Di Pasquale</td>
</tr>
<tr>
<td></td>
<td>Sponsored by GSK</td>
<td></td>
</tr>
</tbody>
</table>
With Care Plus products you can prevent tick bites, remove ticks safely, and test engorged ticks quickly for the presence of the *Borrelia* bacterium in the tick that may cause Lyme disease.

**STEP 1. PREVENT**
- Offering up to 5 hours protection against ticks and up to 10 hours against mosquitoes (Deet 50%)  
- Available in 30%, 40% and 50% active ingredient concentrations

**STEP 2. REMOVE**
- Removes a tick quickly, safely and easily  
- Specially developed tweezers (for nymphs as well)  
- Minimum risk of damaging the tick  
- Including two alcohol wipes

**STEP 3. TEST**
- Indicates the presence of the borrelia bacterium in engorged ticks  
- Provides a 92.99% reliable result within 20 minutes  
- If the result is positive, you can start treatment immediately

[Website: WWW.CAREPLUS.EU/EN]

Care Plus is a trademark of Tropicare, the leading specialist in safe and healthy travel since 1992. With Care Plus products, you are getting the very best for your health.

Tropicare • PO Box 1415 • 1300 BK Almere, The Netherlands • +31 (0) 36 5334711 • info@tropicare.eu
ISTM Committee and Group Meetings

ISTM Leadership Lounge and Secretariat Office, Room 201BC

Sunday, 24 May: 13.00-17.00  Wednesday, 27 May: 08.00-17.00
Monday, 25 May: 08.00-17.00  Thursday, 28 May: 08.00-12.00
Tuesday, 26 May: 08.00-17.00

Sunday, 24 May - All meetings held at the Québec City Convention Center.

ISTM Journal of Travel Medicine Editorial Board
By Invitation Only; 14.00-15.30 in Room 304B

ISTM Publications Committee
By Invitation Only; 15.30-17.00 in Room 304B

ISTM Nurses Reception
Open to All Nurses; 16.00-17.00 in Foyer 2

ISTM Pharmacists Reception
Open to All Pharmacists; 16.00-17.00 in Foyer 3

Monday, 25 May - All meetings held at the Québec City Convention Center.

ISTM Examination Committee
By Invitation Only; 07.00-08.00 in Room 304A

ISTM Nursing Professional Group Council
By Invitation Only; 07.00-08.00 in Room 205B

ISTM Pediatric Interest Group Council
By Invitation Only; 07.00-08.00 in Room 204A

ISTM Psychological Health of Travellers Interest Group Council
By Invitation Only; 07.00-08.00 in Room 304B

ISTM Continuing Professional Development Committee
By Invitation Only; 12.45-14.45 in Room 304A

ISTM Pharmacist Professional Group Council
By Invitation Only; 12.45-14.45 in Room 205B

Tuesday, 26 May - All meetings held at the Québec City Convention Center.

ISTM Liaison Committee
By Invitation Only; 07.00-08.00 in Room 304A

ISTM Migrant and Refugee Interest Group Council
By Invitation Only; 07.00-08.00 in Room 304B
ISTM Committee and Group Meetings, continued

ISTM Student Travel Abroad Group Council  
By Invitation Only; 07.00-08.00 in Room 205B

ISTM GeoSentinel Meeting  
Open to All; 08.00-09.00 in Room 301AB

ISTM Research and Awards Committee  
By Invitation Only; 12.45-14.45 in Room 304B

ISTM Migrant and Refugee Interest Group General Assembly  
Open to All; 18.30-19.15 in Room 200C

ISTM Pediatric Interest Group General Assembly  
Open to All; 18.30-19.15 in Room 303AB

ISTM Psychological Health of Travellers Interest Group General Assembly  
Open to All; 18.30-19.15 in Room 301AB

ISTM Responsible Travel Interest Group General Assembly  
Open to All; 18.30-19.15 in Room 302AB

ISTM Student Travel Abroad Interest Group General Assembly  
Open to All; 18.30-19.15 in Room 200AB

ISTM Responsible Travel Group Council  
By Invitation Only; 19.15-19.45 in Room 302B

Wednesday, 27 May - All meetings held at the Québec City Convention Center.

CISTM14 Scientific Program Committee  
By Invitation Only; 07.00-08.00 in Room 304B

CISTM Local Organizing Committee  
By Invitation Only; 07.00-08.00 in Room 304A

ISTM Professional Education Committee  
By Invitation Only; 12.45-14.45 in Room 304A

ISTM Membership Assembly followed by Cocktail Reception  
Open to All; 17.15-19.30 in Room 200C

Thursday, 28 May - All meetings held at the Québec City Convention Center.

CISTM14 Meeting Review and Recap  
By Invitation Only; 07.00-08.00 in Room 304A
Related Society Meetings

All meetings held at the Québec City Convention Center.

Asia Pacific Travel Health Society Scientific Committee Meeting
By Invitation Only; Tuesday, 26 May, 07.00-08.00 in Room 204A

Asia Pacific Travel Health Society Executive Board Meeting
Open to All; Tuesday, 26 May, 18.45-19.45 in Room 204A

NECTM Steering and Scientific Committee
By Invitation Only; Wednesday, 27 May, 16.15-17.15 in Room 304A
Make sure your clients are well cared for abroad... as you would care for them at home.

Recommend Blue Cross Travel Insurance:
- The most recognized travel insurance worldwide
- Up to $5,000,000 in emergency medical care
- Solid network of preferred medical care providers
- Medical expenses paid directly to the provider when possible
- EXCLUSIVE to Blue Cross — All-risk cancellation coverage*
- Flexible and customized coverage options available
- Bed-to-bed repatriation service

Our clients’ welfare and safety are our top priorities.
qc.bluecross.ca

* Some conditions apply.
Exhibition Schedule

The Exhibits, Posters, and Tea/Coffee Breaks are located on the top level of the convention center in Room 400BC from Monday, 25 May through Wednesday, 27 May. Lunches will be available for purchase in the Expo on Monday and Tuesday.

Exhibition Schedule:

Sunday, 24 May 2015
Welcome Reception, 18.00-20.30

Monday, 25 May 2015
Tea/Coffee Breaks 10.30-11.15 and 16.15-17.00
Lunch Break 12.45-14.45

Tuesday, 26 May 2015
Tea/Coffee Breaks 10.30-11.15 and 16.15-17.00
Poster Tours 10.30-11.15 and 16.15-17.00
Lunch Break 12.45-14.45

Wednesday, 27 May 2015
Tea/Coffee Breaks 10.30-11.15 and 16.15-17.15
Lunch Break 12.45-14.45

DiaResQ®

DIARRHEA RELIEF
Beyond your expectations

Nothing ruins international travel quite like diarrhea. DiaResQ® is a breakthrough medical nutrition product that is fast-acting, well-tolerated and safe. DiaResQ® is a proprietary, patent-pending composition that is specially formulated to provide critical nutrients and other dietary factors to meet the special dietary needs of people with occasional diarrhea.

Key Features and Benefits:

- Provides broad-spectrum relief: effective in diarrhea cases caused by viral pathogens such as rotavirus, as well as those caused by common bacterial pathogens.
- Provides naturally occurring immunoglobulins that bind to and neutralize the causative agents to quickly relieve the diarrhea episode and its symptoms.
- Provides critical micro- and macronutrients and immune factors that promote intestinal health and repair, while at the same time providing protein and energy.
- In three open-label clinical studies DiaResQ® was demonstrated to help normalize intestinal function in less than 24 hours in over 90% of patients tested.
- Orally consumed, well tolerated and has an excellent safety profile. Compliance is easy!
Exhibitor List with Exhibition Locations

| Booth 101: | International Society of Travel Medicine (ISTM) |
| Booth 104: | CDC Traveller’s Health Branch |
| Booth 105: | South African Society of Travel Medicine (SASTM) |
| Booth 204: | Sitata |
| Booth 205: | Royal College of Physicians and Surgeons of Glasgow |
| Booth 301: | Takeda |
| Booth 303: | Classado Bimuno |
| Booth 304: | Valneva |
| Booth 307: | Sanofi Pasteur Limited |
| Booth 403: | Skin Shield Products |
| Booth 501: | GSK |
| Booth 504: | PaxVax, Inc. |
| Booth 505: | Immuron and Paladan Labs |
| Booth 507: | Air Ambulance Card |
| Booth 508: | Health Partners International of Canada (HPIC) |
| Booth 604: | IncaPlex Ltd./IncaClinic |
| Booth 605: | Oxford University Press (OUP) |
| Booth 607: | iJet International |
| Booth 608: | PanTheryx |
| Booth 701: | Shoreland Travax |
| Booth 703: | International Association for Medical Assistance to Travellers (IAMAT) |
| Booth 704: | Tropimed |
| Booth 705: | Steripen by Hydro-Photon, Inc. |
| Booth 801: | Global MediKit |
| Booth 802: | Northern European Conference on Travel Medicine (NECTM) |
| Booth 803: | Asia Pacific Travel Health Conference (APTHC) |
| Booth 804: | Global TravEpiNet |
| Booth 805: | Care Plus |
Exhibition Floor Plan
Room 400BC

Entrance

801  701
802  
803  703

Food Concessions and Tables

804  704
805  705

Food and Beverage Service Tables

501

Entrance

301
403  303

Food Concessions and Tables

204  104
205  105

Food and Beverage Service Tables

604  504
605  505

304

Posters

607  507
608  508

307
Air Ambulance Card: Booth 507
www.AirAmbulanceCard.com
Air Ambulance Card is a membership program that provides worldwide hospital to hospital air medical transportation to residents of the United States and Canada. Our provider network, including Montreal based Sky Service Air Ambulance, transports members without the “medical necessity”, “nearest appropriate facility” and “cost limits” imposed by insurance plans.

Asia Pacific Travel Health Conference (APTHC): Booth 803
www.apths.org
The 11th Asia Pacific Travel Health Conference (APTHC 2016) is aimed at clinicians, physicians and any other healthcare professionals working in the field of travel medicine. The theme of the conference is “Travel Medicine Where it Happens”.

Bimuno®; Clasado Bioscience Limited: Booth 303
www.bimuno.com; www.clasado.com
Clasado researches and develops prebiotics, marketing them as scientifically proven gut health products, under the brand name Bimuno®. Bimuno is the only second generation prebiotic offering additional selectivity and functionality over probiotics and other prebiotics. Bimuno® TRAVELAID was developed to help maintain the gut health of holidaymakers and business travellers.

Care Plus: Booth 805
www.careplus.eu/en
Care Plus is the leading European brand of travel health care products. Now introducing the Care Plus Tick-Test which indicates the presence of the borrelia bacterium (Lyme disease) in engorged ticks. The lateral flow test provides a 92.99% reliable result within 20 minutes offering valuable information for eventual treatment of Lyme.
CDC Travelers’ Health Branch: Booth 104
www.cdc.gov/travel
The CDC Travelers’ Health Branch works to reduce illness and injury in U.S. residents traveling internationally or living abroad. The branch provides travel health advice to international travelers and the health care providers who advise them. The CDC Travelers’ Health produces the CDC Health Information for International Travel, referred to as the “Yellow Book,” the definitive U.S. travel medicine reference for clinicians advising travelers. CDC’s Travelers’ Health website (www.cdc.gov/travel) provides outbreak updates and travel notices, travel-related destination-specific disease information.

Global Medikit: Booth 801
www.globalmedikit.com
Global Medikit is the leading Canadian supplier of travel specific health products. We offer items such as insect repellent, treated mosquito nets, water purification products and travel accessories. Our customers include travel clinics, pharmacies and organizations involved in the protection of the high risk international traveller.

Global TravEpiNet: Booth 804
www.globaltravepinet.com
Global TravEpiNet (GTEN) is sponsored by the US CDC and coordinated by the Massachusetts General Hospital. GTEN’s mission is to advance the health of those who travel internationally. The GTEN Program includes a number of features, including a consortium of clinical sites, out-reach programs, and web tools.

GSK: Booth 501
www.gsk.com
GSK is a world’s leading vaccine company, involved in vaccine research, development and production. We have 14 candidate vaccines in development and our broad portfolio of over 30 vaccines prevent illnesses such as hepatitis A, hepatitis B, diphtheria, tetanus, whooping cough, measles, mumps, rubella, polio, typhoid, influenza and bacterial meningitis. Globally, we have more than 12,000 people working to deliver vaccines safely, every day, to people in 90% of the world’s countries. In 2014 we distributed around 800 million doses of vaccine, 80% of them to least developed, low and middle income countries.
Health Partners International of Canada (HPIC): Booth 609
www.hpicanada.ca
HPIC is a not-for-profit relief and development organization that delivers health and hope to the world's most vulnerable people. We are dedicated to increasing access to medicine and improving health in the developing world without discrimination through the provision of essential medicines & medical supplies, pharmaceutical management and logistics, and capacity-building projects.

iJET International: Booth 607
www.iJET.com
iJET International (iJET) provides intelligence-driven, integrated risk management solutions that enable multinational organizations to operate globally with confidence. iJET’s end-to-end, tailored solutions integrate world-class threat intelligence, innovative technology, and response services to help organizations mitigate risk and protect their people, assets, and reputation. Founded in 1999, iJET is a privately held company headquartered in Annapolis, US with regional offices in London, and Singapore. For more information, please visit www.iJET.com.

Immuron: Booth 505
www.immuron.com

IncaClinic: Booth 604
www.inaclinic.com
Inca Clinic is a complete patient management application for travel clinics. It is a web-based requiring only a standard web browser to run. Inca Clinic simplifies the complexity of managing a patient's travel itinerary, vaccine schedule, medication and other health information. Take out a 15-day free trial.

International Association for Medical Assistance to Travellers (IAMAT): Booth 703
www.iamat.org
IAMAT’s mission is to make the world a healthier place to travel. As an advocate for travelers’ health since 1960, IAMAT protects and improves the well-being of travelers with impartial health information and its worldwide network of English-speaking doctors committed to helping members. IAMAT also awards travel medicine scholarships to enhance patient care abroad.
Exhibitor Information, continued

International Society of Travel Medicine (ISTM): Booth 101
www.ISTM.org
The ISTM, with 3,400 members in 90 countries, is the largest organization of professionals dedicated to the advancement of the specialty of travel medicine. ISTM strives to promote the field of travel medicine through the dissemination of information, providing ample networking opportunities to travel medicine health professionals, developing educational programs and products, facilitating international contacts, and fostering research in travel medicine.

Northern European Conference on Travel Medicine (NECTM): Booth 802
www.nectm.com
The 6th Northern European Conference on Travel Medicine will be held at Queen Elizabeth II Conference Centre in London 1-4 June 2016. A comprehensive programme will cover Travel Health, plus Global Health, and One Health topics, appealing to a broad range of health professionals, from beginners through to experts.

Oxford University Press (OUP): Booth 605
www.oup.com
Oxford University Press publishes some of the most respected medical content in the world, including titles such as CDC Health Information for International Travel, Travellers’ Health: How to stay healthy abroad and the Oxford Textbook of Medicine: Infection. Visit our stand to browse books and enjoy an exclusive conference discount.

Paladan Labs: Booth 505
www.paladinlabs.com
Paladin Labs Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian market. Paladin has a focused marketing and sales organization that has helped it evolve into one of Canada's leading specialty pharmaceutical companies.
PanTheryx: Booth 608
www.pantheryx.com
PanTheryx, a medical nutrition company based in Boulder, Colorado, is focused on the development of medical nutrition products targeting infectious diseases. Our lead product is a breakthrough nutritional intervention for travelers, both adults and children, who suffer from infectious diarrhea.

PaxVax: Booth 504
www.paxvax.com
Founded in 2007, PaxVax, headquartered in Redwood City, California, is a fully integrated specialty vaccine company with a mission to protect people from infectious diseases. Its portfolio includes a licensed vaccine for typhoid, Vivotif® (Typhoid Vaccine Live Oral Ty21a).

Royal College of Physicians and Surgeons of Glasgow: Booth 205
www.rcpsg.ac.uk
The Royal College of Physicians and Surgeons of Glasgow is an educational institution, membership organisation and charity. With more than 12,000 members worldwide, the College is a multi-disciplinary standard setting body, and home to the Faculty of Travel Medicine, supporting medical and non-medical specialists working in this field.

Sanofi Pasteur Limited: Booth 307
www.sanofipasteur.com
Sanofi Pasteur, the vaccines division of Sanofi, provides more than 1 billion doses of vaccine each year. Sanofi Pasteur is the largest company entirely dedicated to vaccines with a broad range of vaccines protecting against 20 infectious diseases. For more information, please visit: www.sanofipasteur.com or www.sanofipasteur.ca.

Shoreland Travax: Booth 701
www.shoreland.com
Since 1986, Shoreland Travax® has been the easy way to access comprehensive, current travel medicine guidance, vetted by a full-time team of more than 20 medical experts, analysts, and editors. The simple web interface allows even novice users to quickly access clear decision-support information and create custom reports for travelers.
Travel practitioners use Sitata because they want the absolute best care possible for their clientele. Sitata is a web-based software solution that provides a fully customizable reference of health and safety information in addition to one of the world’s most advanced digital monitoring systems for health and safety events.

Skin Shield Products is a privately owned New Zealand manufacturer specialising in insect repellents plus other skin protection products. Our brands include a NATO Codified range designed specifically for use of military personnel around the world. So we know our products work even in the harshest of conditions!!

The SASTM’s Mission is to guide the profession in all aspects relating to the practice of travel medicine, liaise with the travel industry, consult with relevant authorities, advise the public and collaborate nationally and internationally on all aspects relating to Travel Medicine. It is privileged to host the 7th Regional Conference of the ISTM in 2016.

SteriPEN is the world’s leading manufacturer of handheld ultraviolet (UV) water purifiers. SteriPEN purifiers quickly and easily make safe drinking water available for travelers visiting areas with questionable water quality. With a SteriPEN water purifier travelers avoid illness, the expense buying water and don't leave a trail of plastic water bottles.
Takeda: Booth 301
www.takeda.com
Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for people worldwide through leading innovation in medicine.

Tropimed: Booth 704
www.tropimed.com
Travel medicine expert program, updated daily since 1992. Tropimed® is for health professionals and those providing travel medical advice. It provides specific information on 231 destinations, as well as epidemiological maps and a lot of additional information. Meet us at the booth No. 704 for a demonstration.

Valneva: Booth 304
www.valneva.com
Valneva is a leading pure play vaccine biotech company developing, manufacturing and commercializing vaccines with a vision to protect people from infectious diseases. Our portfolio includes two vaccines for travelers: IXIARO® for the prevention of Japanese encephalitis and Dukoral® indicated for the prevention of traveler’s diarrhea caused by ETEC and/or Cholera.